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Continuous Processing of Liposomes to Control and Predict Physical 
Properties 
 
Antonio P. Costa, PhD 
University of Connecticut, 2016 
 
Liposomes are specialized drug delivery systems that deliver drugs efficiently and may be used in 
targeted and/or extended-release applications. Currently, the processing and manufacturing of these drug 
products is by batch processing in the pharmaceutical industry. Batch processing has disadvantages such 
as scalability, irreproducibility, down-time between batches and other issues leading to reduced product 
availability, product waste and increased monetary costs. As a way to circumvent traditional problems 
associated with batch processing, the U.S. FDA has published guidance focusing on the continuous 
manufacturing of drug products, quality by design and the incorporation of process analytical technology.  
 
In the current work, a continuous process for the formation of liposomes was developed. This process was 
based on the ethanol-injection process, which includes injecting ethanol with dissolved lipid into an 
aqueous phase. The process included additional downstream processes such as in-line dilution, in-line 
concentrating, and at-line particle size analysis. National Instruments (NI) LabVIEW was used to develop 
the entire process into an automatic, continuous process. All control and measurement devices were 
controlled by a single computer program. The computer program contained algorithms that enabled 
prediction measurement of liposomal characteristics (e.g. particle size, particle size distribution and lipid 
concentration). Moreover, a quality-by-design (QbD) approach was followed from the onset of the 
project. Following QbD minimized the overall risk in developing the system and established an extensive 
understanding of liposomes. With the use of multiple design of experiment studies, algorithms and 
prediction equations were included in the custom-built computer program and established accurate control 
over the liposome formation process. 
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Fig. 4.11 Cryo-TEM micrographs of liposomes for three liposome samples produced using 
different flow conditions. a) 40e:100a sample, b) 40e:150a and c) 40e:375a. Ethanol flow rate = 
e (mL/min); Aqueous flow rate = a (mL/min). 
 
Fig. 4.12 Proposed model for liposome formation from a coaxial turbulent jet mixer in co-flow. 
A schematic of a turbulent jet is shown with a radial ethanol concentration gradient (top left). In 
the liposome formation model, lipid and ethanol molecules aggregate (forming pro-liposomes) as 
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Image not shown to scale. 
 
Fig. 5.1 Schematic representation of the liposome formation stage followed by the ethanol 
dilution stage. Two temperature readings via thermocouples are taken at each stage and a 
contactor (degassing unit) is positioned in some cases at the end of the liposome formation stage. 
 
Fig 5.2 Liposome mean particle size and polydispersity index for both lipid:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes, where lipid refers to either DMPC or DPPC. Both z-average 
particle size (top) and polydispersity index (PDI, bottom) are plotted vs. aqueous phase I flow 
rate (mL/min). 
 
Fig 5.3 Liposome mean particle size and polydispersity index for DPPC:Chol:DPPG (4.5:3:0.4 
molar ratio) liposomes. The mean particle size and PDI is plotted against the temperature (°C) at 
the liposome formation site (see Fig 5.1). The aqueous phase I flow rate was kept constant at 80 
mL/min. 
 
Fig 5.4 Liposome mean particle size and polydispersity index for DMPC:Chol:DPPG (4.5:3:0.4 
molar ratio) liposomes. The mean particle size and PDI is plotted against the temperature (°C) at 
the liposome formation site (see Fig 5.1). The aqueous phase I flow rate was kept constant at 70 
mL/min. 
 
Fig 5.5 A comparison of manual DLS measurement settings on the liposome particle size (z-
average), the PDI and the DLS count rate (kcps). All results were from a single run at either 3, 9 
or 15 seconds. The liposome formulation was the same for all measurements and had a z-average 
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Fig 5.6 Liposome mean particle size and polydispersity index for DPPC:Chol:DPPG (4.5:3:0.4 
molar ratio) liposomes.  The mean particle size and PDI is plotted against aqueous phase I flow 
rate. The flow rates in the bottom plot in red are the DLS flow rates or the flow rate of the 
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Fig 5.7 Liposome mean particle size and polydispersity index (PDI) for DMPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 10 mM Phosphate Buffer.  The mean particle size, PDI and 
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aqueous phase I flow rate is plotted over a period of time. The DLS flow rate was fixed at 1 
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Fig 5.8 Liposome mean particle size and polydispersity index (PDI) for DPPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 10 mM Hepes buffer.  The mean particle size, PDI and 
aqueous phase I flow rate is plotted over a period of time. The DLS flow rate was fixed at 1 
mL/min. 
 
Fig 5.9 Liposome mean particle size and polydispersity index (PDI) for DPPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 10 mM NaCl.  The mean particle size, PDI and aqueous 
phase I (AFR I) flow rate is plotted over a period of time. 
 
Fig 5.10 Liposome mean particle size and polydispersity index (PDI) for DPPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 75 mM NaCl.  The mean particle size, PDI and aqueous 
phase I (AFR I) flow rate is plotted over a period of time. 
 
Fig 5.11 Liposome mean particle size and polydispersity index (PDI) for DPPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 140 mM NaCl.  The mean particle size, PDI and aqueous 
phase I (AFR I) flow rate is plotted over a period of time. 
 
Fig 5.12 Liposome mean particle size (z-average, d.nm) for DPPC:Chol:DPPG (4.5:3:0.4 molar 
ratio) liposomes in 10-140 mM NaCl (green, red, blue) and 10 mM PB (orange).  The mean 
particle size is plotted against the aqueous phase I flow rate and the ionic strength. 
 
Fig 5.13 Liposome zeta potential for DPPC:Chol:DPPG (4.5:3:0.4 molar ratio) liposomes in 10-
140 mM NaCl and 10 mM phosphate buffer.  The zeta potential is plotted against the aqueous 
phase I flow rate.  
 
Fig 5.14 An example of automatic particle size control for HSPC:Chol:DPPG (4.5:3:0.4 molar 
ratio) liposomes prepared in 10 mM NaCl is shown.  The mean particle size, polydispersity index 
(PDI), count rate (kcps) and aqueous phase I flow rate (mL/min) is plotted against time (s). The 
arrows indicate when the user changed the particle size set point in the software. 
 
Fig 6.1: Schematic of the lipid concentration stage consisting of multiple components such as 
pumps, a tangential flow filtration unit, a flow meter and an NIR turbidity sensor. 
 
Fig 6.2: Experimental design of the lipid concentration prediction model based on scattered light 
from an NIR turbidity sensor. 
 
Fig 6.3: Model 2 experimental design for the lipid concentration with factors including particle 
size (d.nm), polydispersity index (PDI), ppm and CU. The PDI was from 0.03 – 0.21, with “low 
PDI” as PDI ≤ 0.1 and “high PDI” as PDI > 0.1. 
 
Fig 6.4: Surface Profile plot for the lipid concentration [Lipid] prediction model. The scattered 
light from the NIR turbidity detector was measured in units of ppm.  ppm vs. particle size (d.nm) 
vs. the total lipid concentration (mM) was plotted. 
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Fig 6.5: The Lipid Concentration prediction model equation based on the study outlined in Fig. 
6.2 and Fig. 6.4. 
 
Fig 6.6: The Lipid Concentration prediction model equation for Model 2. The response for the 
model is the total lipid concentration denoted as [Lipid] and has four factors: particle size (d.nm), 
polydispersity (PDI), ppm and CU. Both ppm and CU are detected by an NIR turbidity meter. 
 
Fig 6.7: An example of how the NIR signal output in PPM is affected by the polydispersity of a 
liposomal formation. The polydispersity index (PDI) was approximately 0.16 for the high PDI 
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Fig. 7.1. Particle size of liposomes under various conditions. Samples either underwent a freeze-
thaw (FT) cycle or a freeze-anneal-thaw (FANNT) cycle. All liposomes were frozen in liquid 
nitrogen (-196°C). All FANNT samples were thawed at 65°C. Both pre-extrusion and post-
extrusion particle size properties are detailed above. The error bar represents the PDI distribution 
width. The inset above each group of data represents the PDI of the samples for pre- and post-
extrusion. 
 
Fig. 7.2. Zeta-potential of the liposome formulation. The zeta-potential is provided for both pre- 
and post-extrusion for the samples listed in Fig. 7.1. 
 
Fig. 7.3. Encapsulation efficiency for samples thawed under various conditions. All samples 
were frozen in liquid nitrogen at -196°C. The samples thawed directly at 65°C represent normal 
freeze-thaw cycling. All other samples underwent a single freeze-thaw or freeze-anneal-thaw 
cycle. The effects on EE% of thawing at temperatures above 0°C and annealing at subzero 
temperatures is demonstrated (n=3). 
 
Fig. 7.4. Cryo-SEM images of PFE-liposomes with tenofovir. In all the images, the 
smooth/darker areas represent the ice phase while the non-smooth/lighter regions are liposomes. 
(A) Sample frozen to -196°C, magnification (mag.) 5,000x. (B) 30,000x mag. of sample from A 
with liposomes clearly visible. (C) Sample frozen to -196°C, annealed at -20°C overnight, and 
then refrozen to -196°C prior to imaging, mag. 5,000x. (D) 30,000x mag. of sample from C. In 
D, the top right hand corner is ice while the rest of the image is of liposomes in an apparent fused 
state. (D Inset) 30,000x mag. of a thin channel of liposomes between the ice-phases. 
  
Fig. 7.5. DSC profile of annealed liposomes. Samples were first frozen in liquid nitrogen (-
196°C) and heated to the annealing temperature (-22°C or -1.4°C) and held at that temperature 
for 10 min (not shown). The sample was then re-cooled to -60°C (shown above). HEPES buffer 
without liposomes was shown as a control. All samples were run in triplicate and the average 
standard deviation was <0.4 in all cases. 
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Chapter 1 
 
Liposomes as Drug Delivery Systems 
1.1 Abstract 
There has been extensive research over the years focusing on liposomes as drug delivery 
systems. Liposomes are vesicles composed of a single lipid-bilayer or multiple/concentric lipid-
bilayers that surround an aqueous core. Liposomal drug delivery systems are designed to 
encapsulate drug substances in the aqueous core and/or incorporate drug substances into the 
lipid-bilayer. The route of administration is often parental but may also be via other routes such 
as intra-muscular or oral. This chapter explains the basic principles of liposomes and is divided 
into two major sections. The first section outlines the liposome formation mechanism and 
liposomal physicochemical properties. The second section outlines liposomal processing 
techniques. 
1.2 Liposomal Basic Principles 
1.2.1 Properties of Lipid Molecules 
Lipid is one of the four classes of biological compounds and the compounds in this class share 
the chemical property of being insoluble in water. Unlike the other classes such as proteins, 
nucleic acids and carbohydrates, lipid compounds have a high degree of structural diversity1. For 
example, lipid compounds may be further subdivided into fatty acids, surfactants, triglycerides, 
phospholipids, terpenes, steroids, and lipid soluble vitamins. Lipids that are typically used in the 
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formulation of liposomes are amphiphilic in that these compounds have both a hydrophilic and a 
hydrophobic region. The chemical structure of these lipid compounds consist of a backbone 
region (e.g. glycerol or sphingosine), a hydrophilic head group (e.g. phosphatidylcholine), and 
two hydrophobic hydrocarbon tails. The head group and hydrocarbon tails are esterified to the 
backbone and form specific classes of lipids (e.g. glycerophospholipids). Many different 
esterified groups exist, forming an abundance of lipids. With respect to head groups, these 
groups may be neutral/zwitterionic (e.g. phosphatidyl choline) or have either a positive or 
negative charge. Moreover, hydrocarbon chains may be saturated or unsaturated and may be 
derived naturally or synthetically. Saturated lipids do not have double bonds in the hydrocarbon 
chains while unsaturated do. Typically, unsaturated lipids used in liposomes consist of either 
only one or two sites of double bonds, as highly unsaturated lipids would not form liposomes as 
a result of their packing parameters as detailed below. 
 
Individual lipid molecules have an important property known as the lipid phase transition 
temperature. This property outlines a transition where the lipid molecule goes from a gel, solid-
ordered phase (below the Tc) to a fluid, disordered phase (above the Tc)2. This transition can be 
determined by differential scanning calorimetry3-4. With respect to liposomes, this transition may 
cause in increase in membrane permeability5. Saturated lipids generally have a higher lipid 
phase-transition compared to unsaturated lipids. A high lipid phase-transition keeps the lipids in 
the gel form at physiological temperature or above; which can increase liposomal in vitro and in 
vivo stability. For lipids with a low phase transition temperature, the lipid may be disordered in 
the lipid bilayer at storage and processing conditions, leading to increased molecular 
permeability6 (e.g. drug leakage) and reduced liposomal stability. The incorporation of 
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cholesterol in a lipid bilayer is known to be an important addition to liposomes as it broadens or 
diminishes the lipid phase-transition and increases liposomal stability7-8. Cholesterol does this by 
forming a new phase, the liquid, ordered phase9. This phase exists below and above the lipid 
phase transition temperature of the pure lipid component and reduce the intensity of the phase 
transition10. Therefore, it may be important to incorporate cholesterol into liposomal 
formulations for drug delivery applications. 
 
Depending on the application, different types of lipid may be incorporated into liposomes to 
modify liposomal properties. For example, fusogenic lipids such as DOPE are used in cellular 
delivery of nucleic acids to improve endosomal escape. The fusogenic property is one that causes 
the liposomes to fuse with the cellular membrane11-12 or with the endosomal membrane13, 
resulting in the release of contents into the cytoplasm. The liposomes fuse with the endosomal 
membrane post cellular uptake14 causing the liposome and the nucleic acid to reach the 
cytoplasm. Another type of lipid is DSPE-mPEG and its derivatives. The chemical structure of 
these lipids consists of a phosphoglycerol lipid (e.g. DSPE) linked to a long chained 
polyethylene-glycol (e.g. mPEG-2000). This class of lipids adds a polymer layer to the outside of 
the liposome and enhances liposomal stability. These liposomes were originally termed “stealth” 
liposomes15 as the hydrated polymer layer considerably delays liposomal cellular uptake once 
administered in vivo. In addition, these polymer lipids may be modified to introduce targeting 
moieties to the outer-leaflet of the lipid-bilayer. These targeting moieties are important for a 
variety of applications when in vivo passive targeting is insufficient. 
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Another property of lipid molecules is the critical packing parameter. The critical packing 
parameter, P, is defined as: 
 =  ∗  
 
Where V is the volume of the hydrophobic region of the lipid, a is the cross-sectional polar head 
group area where the head group connects with the hydrophobic region, and l is the length of the 
hydrocarbon chains. The importance of the critical packing parameter is that it indicates the lipid 
structure/phase that may form for that individual lipid. Different lipid structures include: lamellar 
phase (p~1), hexagonal I phase (P<1) and hexagonal II phase (P>1)10. Lipid molecules that have 
P~1 will form liposomes under certain conditions (see section 1.2.2), whereas lipid molecules 
with P<1 and P>1 will form micelles or inverted micelles, respectively. In addition, this packing 
parameter can be used to determine whether lipid mixtures will form liposomes, i.e. certain 
weight ratios of lipids of different phases may result in an average packing parameter of 
approximately 1, thus forming liposomes. Moreover, critical packing parameters are known for 
the vast majority of lipids used in liposomal applications.  
 
1.2.2 Thermodynamics of Liposome Formation 
Since lipid molecules used in liposome preparations are amphiphiles and have a large 
hydrophobic region, these molecules are insoluble in aqueous medium. Depending on the 
aqueous phase weight percentage with respect to lipid weight percentage and temperature, 
different structures may form. For lipids with a P~1 and at high lipid weight percentages, a 
stacked lamellar network will form. For lipids with P>1 or P<1, stacked hexagonal I phase 
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cylinders or stacked hexagonal II phase cylinders will form, respectively. In order to form 
liposomes, the lipid weight percentage must be low and sufficient energy must be applied to the 
system. Due to these constraints, liposomes are best defined as being in a thermodynamically 
metastable state. Along the same line of thinking, liposomal bilayers may be considered as 
kinetic energy traps. With this in mind, liposomes will tend to aggregate over time and approach 
a thermodynamically stable state, i.e. a stacked lamellar phase. Therefore, the addition of 
charged lipids or polymeric lipids must be added to the lipid mixtures to establish long term 
physical stability of liposomes. 
 
1.2.3 Liposomal Physicochemical Properties  
Physicochemical properties of liposomes include hydrodynamic radius (size), polydispersity, 
lamellarity, mechanical properties, gel-liquid phase-transition temperature, surface properties 
(e.g. zeta-potential and polymers), oxidation and hydrolysis. All of these properties are important 
for both formulation stability and pharmaceutical application. 
 
The particle size of liposomes ranges from 30 nm to >1000 nm. Liposomes can be formed as uni-
lamellar or multi-lamellar vesicles. Moreover, unilamellar liposomes are normally classified as 
small-unilamellar vesicles (SUVs, < 100 nm in diameter) or large uni-lamellar vesicles (LUVs, 
≥100 nm in diameter). The zeta-potential is an important characteristic that may signify liposome 
stability. The zeta-potential is the electric potential at the shear plane of the particle, where the 
shear plane is an imaginary layer of ions bound to the surface of the particle. Particles are 
considered to exhibit full electrostatic stabilization when the zeta-potential is > |30| mV, or >|60| 
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mV for optimum stability.16 In addition, polymers such as polyethylene-glycol (PEG) increase 
the liposomal steric stability and increase in vivo circulation times (biological stability)17-18.  
 
1.2.4 Liposome Formulation Techniques 
There are a vast number of techniques to formulate liposomes. Each technique has its advantages 
and drawbacks. Some of the more common methods include thin-film hydration, reverse-phase 
evaporation, adaptive-focused acoustic (AFA) technology and ethanol (or organic solvent) 
injection. 
 
Briefly, the thin-film hydration method includes dissolving the lipid (in powder form) to 
chloroform and subsequently removing the chloroform/methanol followed by hydration (with an 
aqueous phase). This method is simple but uses large amounts of United States Pharmacopeia 
(USP) Class 2 residual solvents19. Under this class, the permitted daily exposure (PDE) of 
chloroform is 60 ppm and the PDE of methanol is 3000 ppm19. Reverse-phase evaporation is a 
demulsifaction method where an immiscible organic solvent (e.g. diethyl ether) is depleted. 
AFA, on the other hand, does not require any organic solvents. AFA uses focused ultrasound to 
induce cavitation and break apart the lipid powder/formed liposomes in an aqueous medium. The 
downside to this technique is that it requires a relatively long amount of time to dissolve the 
lipid/form liposomes and some drug substances may not be stable during sonication. The last 
method is the ethanol injection method. This method was chosen for the current work since it is 
naturally a continuous process. Briefly, lipid is dissolved in ethanol and the ethanol is injected 
into an aqueous medium. During this process, liposomes are formed. This process can be 
controlled by a variety of factors, but the exact mechanism is remains unclear. In addition, 
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ethanol is considered a USP class 3 residual solvent and is acceptable under 5000 ppm or 50 
mg/day19, which is more attractive than class 2 residuals solvents. 
 
Once the liposomes are formed, additional steps must be included to produce a final drug 
product. These steps include the addition of drug molecules, downsizing techniques, 
concentration and purification. For the ethanol injection technique, drug molecules may be added 
to the ethanol phase or to the aqueous phase (depending on solubility). Drug substances may 
even be added after the liposomes are formed, and an additional step such as freeze-thaw cycling 
would need to be incorporated to encapsulate the drug substance. 
 
1.2.5 Intercalation of Molecules in the Liposomal Membrane  
For the ethanol injection method, drug substances can be added to the aqueous and/or organic 
phase prior to liposome formation or to the aqueous phase after liposome formation. Drug 
substances that are soluble in an organic phase, e.g. ethanol, may interact with the nonpolar, 
hydrocarbon chain of the lipid. In this way, these molecules will be either fully or partially 
embedded in the lipid-bilayer. Molecules that are water-soluble may be added to the aqueous 
phase and these molecules will be entrapped by the liposomes upon formation. One downside to 
the ethanol injection method for water-soluble drugs is that this method is highly dilutive; 
meaning the amount of lipid injected into the aqueous phase is very low. For this reason, the 
amount of drug entrapped during the liposome formation process will be extremely low (e.g. 
~1%). Therefore, the drug must be lipophilic or additional techniques will need to be 
implemented to encapsulate the drug. One way to encapsulate larger quantities of water-soluble 
drugs is to concentrate the liposomes and then undergo freeze-thaw cycling (see section 1.2.6). 
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This approach is suitable for small molecules and proteins. For weak acids and weak bases that 
are able to permeate the lipid membrane, another approach termed active loading has been 
widely used (see section 1.2.7).  
 
1.2.6 Passive Encapsulation: Freeze-Thaw Cycling  
Freeze-thaw cycling is a processing technique that impacts the liposomes in multiple ways. This 
technique has been shown to: reduce the lamellarity of multi-lamellar liposomes20; form a more 
monodispersed system from a polydispersed system by disrupting the lipid-bilayer21; and  
increase drug diffusion into the liposomes – resulting in higher drug encapsulation efficiency22-
24
. Briefly, this technique consists of mixing pre-formed liposomes with drug followed by 
immersion in a << 0°C bath (typically liquid nitrogen). The sample is allowed to completely 
freeze and is then thawed in a second bath above 0°C (typically 25-50°C). This cycle may be 
repeated multiple times. During each cycle, drug diffuses into the aqueous core of the liposome 
and become passively encapsulated. The encapsulated quantity is highly dependent on the lipid 
concentration and liposomal particle size25. Achieving large trapping volumes >40-50% is 
generally not feasible with this approach. A modified freeze-thaw cycling technique termed 
freeze-anneal-thaw cycling has been developed to reduce the number of freeze-thaw cycles and 
increase liposome permeability, thus allowing more drug molecules to enter the liposomes26. 
Moreover, this technique takes advantage of cryo-concentration of drug substances to increase 
the amount of drug molecules encapsulated. However, this approach also suffers from relatively 
low trapping volumes.  
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1.2.7 Active or “Remote” Loading of Molecules 
Active loading is a suitable technique to load weak acids or weak bases into the aqueous core 
and achieve high load efficiencies (>90%)27-28. This technique has been used for the FDA-
approved Doxil® drug product. There are different strategies to active loading, and each strategy 
is typically drug dependent. However, the basic idea behind each strategy is to establish an ion 
gradient or pH gradient29-31. Briefly, the liposomes are first formed with a large amount of salt in 
the liposomal interior (e.g. 300 mM ammonium sulfate, pH=6). The external phase salt is 
exchanged via dialysis or other means with an isotonic medium with a pH near the pKa of the 
drug. The difference in pH of the internal phase and external phase, along with an ion gradient, 
establishes an electrochemical gradient across the lipid bilayer32. The drug is then added to the 
external phase and is partially unionized since the pH is close to the pKa. The unionized form of 
the drug permeates the lipid bilayer and ionizes inside the liposomes since the pH << pKa (i.e. 
for a weak base). Since ionized drugs do not permeate through the lipid bilayer the drug then 
becomes trapped inside the liposomes. 
 
1.2.8 Liposomal Drug Products Overview 
Liposomes as drug delivery carriers have been successfully developed and marketed in the 
pharmaceutical industry. To date, liposomes have been used to treat or mitigate cancer, macular 
degeneration, fungal infections and vaccines with approved products such as Doxil®, 
Ambisome®, and Exparel®, respectively33. Currently, there are eight FDA-approved drug 
product lines classified as “injectable, liposomal” according to the drugs@FDA database. In 
addition, there are over 100 open clinical trials that are investigating new liposomal drugs, drug 
combinations or new indications for existing liposomal drug products34. 
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1.3 Continuous Processing of Liposomal Drug Products 
1.3.1 Batch vs. Continuous Manufacturing 
A batch-type manufacturing process is one in which bulk material is charged and processed as a 
unit and that entire unit is processed from stage to stage. Upon completion, the entire product is 
discharged. For multiple stage processing operations, all material must be finished processing in 
the first stage before being charged into the next stage. A continuous manufacturing process is 
one in which raw material is constantly charged while the product is discharged35. For processing 
at multiple stages, material is constantly being charged and discharged through each stage until 
the material reaches the final stage. In this case, there is a final product at one end with raw 
material at the other. For a continuous process, the term “batch” or “lot” is still applicable and 
refers to a drug product that has uniform character and quality produced over a unit time. 
 
There are advantages and disadvantages of both systems and in some cases; continuous 
manufacturing may not be entirely possible. The conventional approach of batch processing has 
been successful in the pharmaceutical industry. However, recent advances in technology such as 
those related to process analytical technology (PAT) have opened the door for improvements in 
the manufacturing and regulation of pharmaceutical processing. In general, batch manufacturing 
has disadvantages related to open system transfers, batch-to-batch variations, scale-up issues, and 
supervised production. As the production of liposomes is a multi-stage process, the transfer of 
material from each stage may lead to material loss and contamination. Both of which will further 
result in batch-to-batch variations and possibly a low quality product. In some cases, quality 
assurance of a batch process may be high by rejecting batches; however, this results in wasting 
material and increasing processing and production timelines. Lastly, scaling up a batch process 
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typically leads to further problems. Since smaller batches are made for clinical trials, larger 
batches may result in formulation differences in the final product. Due to the possibility of 
formulation differences, additional testing needs to be performed to validate and confirm that the 
increase in batch size did not alter the formulation – this increases production time and 
regulatory burden. 
 
On the other hand, a continuous manufacturing process avoids many of the issues associated 
with batch processing. There are no open system transfers (except possibly for the final product), 
low variations in the formulation as long as the system is running under set conditions, minimal 
supervision is required and no scale-up issues. To increase the amount of final product, the only 
variable that needs to be adjusted for is time. Ideally the same equipment can be used for a small 
pilot study and for large production batches. To this end, continuous manufacturing may reduce 
production time, costs and regulatory burden compared to a batch process. 
 
1.3.2 Process Analytical Technology 
Process analytical technology is a framework outlined by the U.S. FDA that combines 
components such as multivariate tools, process analyzer and process control tools as a means to 
measure and control critical quality attributes of drug products.36 For continuous measurements, 
measurements are either taken in-line, at-line or on-line. In-line refers to measurements taken 
where the sample was not removed from the process stream. At-line measurements refer to 
samples being removed from the process stream, analyzed and discarded. On-line measurements 
refer to samples being removed from the process stream, analyzed and may be diverted back to 
the process. One such process analyzer is for particle size and zeta potential measurements. Two 
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techniques considered for the current work were: (1) dynamic light scattering (DLS), or (2) 
acoustic (particle size) and electro-acoustic (zeta-potential) spectroscopy. Both dynamic light 
scattering and acoustic spectroscopy will be explained in more detail in Chapter 5.  
 
In order for these techniques to be implemented in the continuous process, a flow cell is required 
that connects the process stream to the process analyzer. In addition, the process analyzer must 
have a means of communication to a computer and/or data acquisition device. For example, the 
Malvern Zetasizer® can be used in conjunction with Malvern Link-2 software to communicate 
with National Instruments (NI) LabVIEW™. A custom computer program can be written in NI 
LabVIEW™ that controls the entire continuous process37. The Malvern Link-2 software uses an 
OPC server/client architecture and provides a way to extract data such as the particle size and 
zeta potential and to send measurement information from and to the Malvern Zetasizer, 
respectively. In the current work, the goal was to add real time particle size analysis (necessary) 
and zeta-potential (if possible) measurements to the system. 
 
Raman spectroscopy may also be utilized as a PAT analyzer. This technique has the ability to be 
used for both quantitative and qualitative purposes.38 The fundamentals of Raman spectroscopy 
are based on the inelastic scattering of electromagnetic radiation by exciting the sample at a 
specific wavelength. The excitation wavelength will depend on the laser source and may range 
from the visible light to the near infrared wavelengths. The outputs of this technique are Raman 
bands or vibrational modes of a molecule. Moreover, the intensity of the Raman bands is 
proportional to the inverse fourth power of the excitation wavelength. This means that a laser 
source with a shorter wavelength would provide a more intense signal. However, molecules may 
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also fluoresce in the visible light range, which would create background noise. To avoid this 
noise, a higher wavelength may be chosen. There are numerous applications of Raman 
spectroscopy and it can be used to quantify and understand a process. For example, metoprolol 
tartrate was quantified in the range from 10-40% (g/100mL).39 Moreover, a qualitative study on 
doxorubicin interacting with malignant hepatocytes and the overall impact on the lipid content in 
the hepatocytes was reported.40 Lastly, Raman spectroscopy may be used to determine drug 
crystallinity or amorphous content.41 
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Chapter 2 
 
Specific Aims and Tasks 
2.1. Specific Aim 1 
Design and Fabrication of a Continuous Process to form Liposomes based on the Ethanol 
Injection Technique 
The ethanol injection method was chosen since this method does not require the use of 
potentially carcinogenic organic solvents. Moreover, this method is inherently a continuous 
method since lipid dissolved in ethanol is injected into an aqueous phase and the liposomes form 
during this process. The control of processing conditions was achieved by creating a custom-
built computer program (National Instruments (NI) LabVIEW) to communicate with the entire 
process/system. A block diagram of the process is outlined in Fig. 2.1. A computer program 
connected to a data acquisition device controlled the entire process (Fig. 2.2). The first stage was 
the lipid mixing stage, where multiple sources of lipid dissolved in ethanol were mixed at the 
specified ratio. The next stage was the liposome formation stage, where an aqueous stream was 
mixed with the lipid+ethanol stream. This stage also included a second aqueous stream that was 
used to dilute the ethanol down to approximately 5% vol. ethanol. The last major stage was the 
concentrating stage, where the liposomes were concentrated in-line to a desired concentration. It 
was hypothesized that by controlling processing conditions in the continuous process based on 
the ethanol injection method, critical quality attributes of liposomes (e.g. particle size, size 
distribution and zeta-potential) would be precisely controlled. 
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2.1.1 Task 1 
Implement a QbD Approach to Design/Fabricate the Ethanol-Injection System 
As an initial step, a QbD approach was implemented to reduce the overall risk associated with 
different aspects of this work. A risk assessment outlining each processing step to increase 
chances of success was conducted. This approach aids in developing a full understanding of each 
stage before fabrication to avoid unnecessary costs and to support time management. 
 
2.1.2 Task 2 
QbD Approach to Determine Factors involved with Liposome Formation 
As a continuation of the QbD approach, design of experiment studies were completed to 
understand how liposomes were formed and to ultimately determine a mechanism of liposome 
formation. The first step was to understand the current system and its limitations. For example, it 
was necessary to determine the minimum and maximum controllable flow rates for both the 
ethanol and aqueous phases. Also, the system initially needed to be adaptable such that tubing 
and other parts could be exchanged to test the impact of different dimensioned parts. Once the 
limitations of the system were known, a list of factors was generated that were thought to impact 
the liposome formation. This list of factors was generated from a literature review and known 
system constraints. Below is a list of factors that may impact liposome formation: (1) lipid 
concentration; (2) ethanol flow-rate; (3) water flow rate; (4) ethanol-phase temperature; (5) 
water-phase temperature; (6) tubing diameters (both water and ethanol). 
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The outcomes or responses of the DOE study for the liposome formation process were critical 
quality attributes of liposomes such as particle size, polydispersity index (PDI) and zeta-
potential. Factors that demonstrated statistical significance for critical quality attributes are 
considered key factors and were studied in more detail.  
 
2.1.3 Task 3 
Introduce Process Analytical Technology to the System 
The overall goal of PAT is consistent with the FDA’s drug quality system: “…quality cannot be 
tested into products; it should be built-in or should be by design.”42 When quality is built into a 
system, the product quality is ensured, the products are processed to achieve certain 
characteristics based on a mechanistic understanding, real time quality assurance is provided, the 
manufacturing is more likely to accommodate current regulatory policies and procedures, and 
lastly, the risk-based approach reduces the chances of poor product quality.  
 
A PAT tool is any tool that fits under the following categories: (1) acquire/analyze data 
(multivariate capable); (2) processing analyzer; (3) process control tool; and (4) management 
tool that allow for continuous improvement and knowledge of a process. Multivariate tools may 
be statistical designs of experiments described previously. Combining these DOE studies with 
some type of computer software (as a process control tool) to control and alter processing 
conditions would fit under this category. In this case, a predictive equation or results from a DOE 
study is then used to adjust the final formulation when process variations are encountered. 
Process analyzing tools can be implemented in three ways: (1) at-line, or where a sample is 
removed and isolated from a system; (2) on-line, or where a sample is diverted, measured and 
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returned to the process; or (3) in-line, or where a sample is measured directly in the process. 
Process analyzers generate large amounts of data that can be collected and stored for quality 
control purposes and reporting. Lastly, analysis of data to build on the understanding of the 
overall process will aid in a continuous learning and improvement of the processing stream, 
which will facilitate regulatory acceptance and provide evidence to support alterations to an 
existing process. 
 
An example of a possible at-line or on-line measurement is using the Malvern Zetasizer with a 
flow-cell attachment. A solenoid valve opens and directs the flow of the sample to the Zetasizer 
flow cell and closes once enough sample is loaded in the cell. The Zetasizer then performs a 
measurement and this information is sent to the custom-built LabVIEW program. In the 
LabVIEW program, this value is analyzed and process conditions (e.g. flow rates) are altered 
based on the aforementioned DOE studies to re-adjust the particle size to be within quality 
control limits. 
2.2 Specific Aim 2 
Impact of Freeze-Anneal-Thaw Cycling on Liposomal Drug Encapsulation Efficiency and 
Particle Size 
Freeze-Thaw cycling is a technique used for multiple purposes, one of which is to encapsulate 
drug substances inside liposomes. By understanding the mechanism in which drug substances 
enter a liposome, it may be possible to incorporate this technique in the continuous processing of 
liposomes detailed in Specific Aim 1.  
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Once liposomes are formed, the only way for water soluble drugs to enter liposomes is via active 
or “remote” loading. However, active loading is only suitable for weak acids/bases. Other water-
soluble molecules such as proteins, nucleic acids, and small molecules cannot diffuse into the 
liposomes. The only way to get these molecules into liposomes is to break the liposomes or 
cause the lipid-bilayer to become permeable enough to allow diffusion of these molecules into 
the core of the liposome. It was hypothesized that a more detailed understanding of a possible 
mechanism on how drug substances enter liposomes during the freeze-thaw cycling technique 
will aid in the development of a modified method for entrapping drug substances. It is further 
hypothesized that due to permeability changes in the lipid-bilayer during freezing, in conjunction 
with cryo-concentration of liposomes and drugs, increased amounts of drugs will enter the 
liposomes and become encapsulated. Additionally, it is necessary to maintain physical properties 
of the liposomes such as particle size and zeta-potential during this process. 
 
2.2.1 Task 1 
Design a Formulation that is Stable against Freezing (i.e. minimal changes in physical 
properties). 
To determine the impact that freezing has on the liposomal encapsulation efficiency, it is 
important to perform these studies with a formulation that will not change liposomal critical 
quality attributes throughout this process. Moreover, comparing the encapsulation efficiency 
from a monodispersed population of liposomes to a polydispersed population of liposomes is 
incorrect. Therefore, a stable liposome formulation was investigated and the addition of cryo-
protectants (e.g. sugars) to the formulation was assessed. 
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2.2.3 Task 2 
Determine Factors that may Influence Drug Substance Encapsulation Efficiency. 
During the freeze-thaw cycling step, the following factors were thought to impact how drug 
substances enter liposomes: (1) freezing rate; (2) final freeze temperature; (3) thawing rate; (4) 
final thawing temperature; (5) annealing (or holding) time at subzero temperatures; (6) annealing 
temperature. The first four factors have been previously reported on in the literature, but only in 
the release of drug substances or chemical markers, not in the encapsulation. It was further 
hypothesized that water crystallization and ice growth and subsequently cryo-concentration will 
influence the amount of drug substance that enters the liposomes. In this case, annealing the 
sample at a specified subzero temperature for a period of time promotes ice growth followed by 
increased drug encapsulation. 
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2.3. Figures 
 
 
 
Figure 2.1: Block diagram of the entire system. Arrows indicate the flow direction of the 
process.  
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Figure 2.2: Front panel of the custom computer program. The computer program is divided 
into five parts: lipid mixing, aqueous phase/buffer, aqueous phase dilution, tangential flow 
filtration (TFF) system and particle size. 
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Chapter 3 
 
Quality by Design: Risk Assessment of Continuous Processing Stages 
3.1 Introduction 
The quality by design (QbD) framework is a set of principles that aids in maintaining quality and 
managing risks associated with product development. Some of these principles applicable to the 
current work include: (1) identifying/determining critical quality attributes (CQAs), (2) selecting 
an appropriate process, (3) identifying material and processing parameters that impact the CQAs 
and (4) form a relationship between material and process parameters.43 To identify material and 
process parameters, risk assessment tools such as cause and effect diagrams and a 
severity/frequency analysis chart were generated. In addition, to form relationships between 
materials and process parameters, design of experiment studies were used. A more detailed 
explanation for drug product development is outlined in the Q8(R2) Pharmaceutical 
Development43.  
 
In the case of liposomes, CQAs may include particle size, particle size distribution, zeta-
potential, drug loading (lipophilic drug), encapsulation efficiency (hydrophilic drug), final 
drug/lipid weight ratio and drug release rates. In the current work, the focus was primarily on the 
first three CQAs listed above. Since a part of this work was to develop a continuous process to 
form liposomes, different liposome preparation techniques were compared and analyzed at the 
onset of the work to determine whether an existing approach could be modified into a continuous 
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process. After a literature review and preliminary experiments, material and process parameters 
were identified that would impact CQAs. Lastly, design of experiment studies were performed 
for multiple stages of the continuous process that related material properties to process 
properties. 
3.2 Risk Assessments 
3.2.1 Liposomal Process Selection 
Prior to any work being completed, an initial task was to compare different liposome processing 
techniques and attempt to de-risk implementing the process as a fully continuous process. As 
described chapter 1, there are many approaches to process liposomes. Two approaches that were 
initially considered were the thin-film hydration method44 and the ethanol injection method45-46. 
At the onset, it was known that the thin film hydration method would end up being a semi-
continuous process, as opposed to continuous. One way to form a risk assessment is by using a 
severity-frequency analysis. This type of analysis identifies risks associated with each process. In 
this case, the severity is an indication of how likely the risk may negatively impact the ability of 
each technique to be used in a continuous process. The frequency indicated how often the risk 
would occur. Even though a risk analysis may be subjective in some cases, it does provide 
significant insight into what may develop into future problems. From Fig. 3.1, it is clear that for 
the listed risks, the ethanol injection process has an overall lower risk when compared to the 
thin-film hydration method. Three key risks are the lipid loss, lipid solubility and whether the 
system is inherently continuous. When considering the thin-film hydration process, this approach 
requires dissolving the lipid in an organic solvent followed by solvent removal and then adding 
an aqueous phase to promote lipid hydration. This process would resemble more of a batch 
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process and only additional downstream processing may be continuous, resulting in a semi-batch 
process followed by a continuous process. In addition, this approach would most likely lead to 
lipid loss since the hydrated lipid may cause the aqueous phase to be highly viscous. As it is 
more difficult to transfer a high viscosity mixture, the risk associated with sample loss would be 
higher. 
 
To the contrary, the ethanol injection approach is inherently continuous, i.e. the ethanol with 
dissolved lipid is injected directly into the aqueous phase forming liposomes. In addition, lipid 
loss would be negligible since the entire amount of dissolved lipid should form liposomes. 
However, one drawback is that not all of the phospholipids (especially charged lipid) may be 
soluble in ethanol at high concentrations. This low solubility may introduce limitations on 
preparing some liposomal formulations using this technique. The overall risk is lower for the 
ethanol injection approach compared to the thin-film hydration method; therefore, the ethanol 
injection approach was selected as the process for this work. 
 
3.2.2 Ethanol injection Process Stages: A Risk Analysis 
A risk analysis was performed on the processing stages to adequately outline any possible issues 
that may arise during the fabrication and development of the system. From Fig. 2.1, the main 
stages include: (1) data acquisition, (2) lipid mixing, (3) liposome formation and (4) liposome 
concentrating. In addition to these main stages, process analytical technology (PAT) was 
incorporated into the process and was used to control the entire process. Each PAT was further 
analyzed in an attempt to de-risk the implementation process. Fig. 3.2 is a risk analysis for the 
entire process with the single effect of forming a “quality liposome formulation”. For a quality 
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liposome formulation, the process would need to achieve sufficient control (e.g. control of 
particle size and particle size distribution), be reproducible and accurate, and have the ability to 
be adaptable to cover formulation changes. For example, if liposomes with a mean diameter of 
80 nm are initially sought, but after in-vitro and/or in-vivo studies it is determined liposomes 
with a mean diameter of 150 nm are more efficacious, then the system should be adaptable for 
such modifications. Limitations for every system exist and these limitations are clearly outlined 
throughout this work.  
 
3.2.2.1 System Requirements 
At the onset of design process, outlining the system requirements to achieve a continuous 
process was important. One property was the materials that were selected. Since ethanol and 
lipid interact with certain polymers and metals, the chemical compatibility of different materials 
were assessed as a basis for selecting processing components such as solenoid valves and tubing. 
When it was possible, 316 stainless steel was chosen for its high chemical resistance and 
ruggedness. In addition, many processing components are made up of multiple materials that are 
in contact with the liquids and each of these materials (e.g. o-rings) needs to be confirmed for 
chemical compatibility.  
 
Other properties were: (1) type of data acquisition system, (2) types of sensors that would be 
required to monitor/control the entire process and (3) power requirements to run the entire 
system. Different types of data acquisition systems exist, e.g. real-time, embedded systems and 
PC-based systems. Since it was determined early on that PAT would be incorporated in this 
process, a PC-based system was chosen as some PAT devices can only be controlled via 
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software packages designed for PC-based systems and not embedded systems. For this reason, 
a PCI eXtensions for Instrumentation (PXI) data acquisition system was chosen as this system is 
PC-based, is accurate, an industry standard and is adaptable for many measurement types.  
 
Measurement type refers to the signal that is either being generated or acquired. Examples of 
measurement types include analog signals and digital signals. Analog signals may be subdivided 
further, e.g. voltage and current signals. Digital signals may also be subdivided, e.g. frequency 
measurements and counters. As noted above, the PXI data acquisition system is capable of 
generating and acquiring many signals, but such a system requires specific modules designed for 
each measurement type to be selected. As an example, one module may be only for generating 
analog/digital signals (typically 0-5 volts) while another module may be only to acquire 
analog/digital signals (0-10 volt range). Additional modules may be to directly measure the 
temperature from thermocouples or to measure the frequency of incoming signals (e.g. devices 
referred to as “counters”). 
 
The third property is the power requirement for the various sensors. Only 12 or 24 volt direct 
current (VDC) sensors were used so that the number of power supplies was reduced. Sensors and 
devices are available with many different configurations and to successfully implement all of the 
sensors into a single system; it is desirable for the sensors to share similar characteristics. 
 
3.2.2.2 Lipid Mixing 
The system consists of multiple tanks, each of which may hold either pure ethanol or ethanol 
with dissolved lipid. For the event that multiple types of lipid are required, individual lipid 
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molecules or drug molecules may be added to each tank. In order to form a homogenous mixture 
of lipid or lipid and drug prior to forming liposomes, a lipid mixing process was implemented 
into the design. The lipid mixing process is when the lipid or drug, dissolved in ethanol, is mixed 
prior to entering the aqueous phase. The mixing was achieved by the use of solenoid valves, flow 
meters and precise flow control. In addition, a static mixer was incorporated to create turbulence 
and further induce mixing. 
 
3.2.2.3 Liposome Formation with Dilution 
The liposome formation (Chapter 4) with dilution (Chapter 5) stage can be divided into two 
parts, i.e. liposome formation and ethanol dilution. The liposome formation refers to when the 
ethanol with dissolved lipid or drug is mixed with the aqueous phase, forming liposomes. The 
dilution stage is in-line with the formation stage and adds an additional amount of aqueous 
medium to the liposomes, causing a dilution with respect to the ethanol content and the lipid. For 
both parts of this stage, controlling the flow rate was important as it was previously determined 
that flow rates impacted the liposome formation process. In addition, tubing diameters and the 
liposome formation injection port design were also considered. For example, changing the inner 
diameter of the tubing will cause changes in the velocity of the liquid traveling through the 
tubing. The flow velocity ratio of the aqueous phase to the ethanol phase was initially considered 
as a potential critical factor that would influence the formation of liposomes. 
 
3.2.2.4 Concentrating Liposomes 
A concentrating stage was implemented after the liposome formation and dilution stages. This 
stage was added to provide additional control over the final formulation. When forming 
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liposomes, the initial lipid concentration is low to prevent non-liposomal structures from 
forming47. In addition, a dilution stage was added at the end of the liposome formation stage 
(Chapter 5). This dilution stage was incorporated to reduce the overall ethanol percentage down 
to approximately 5% volume ethanol. By reducing the ethanol stage, the total amount of 
lipid/drug would also be reduced. In order to reach lipid concentrations suitable for 
pharmaceutical applications, the liposomes were concentrated. For the concentrating stage, the 
type of filtration unit and the properties of the filtration unit were assessed. For in-line 
processing, a tangential flow filtration unit was chosen. In order to incorporate this system for 
the in-line process, it was necessary to investigate possible filtration rates and the hhgenerated 
filtration pressures.  
 
3.2.3 Risk Analysis of Process Analytical Technology 
In addition to the process stages, PAT was incorporated in the overall design. The purpose of 
adding PAT was to implement enhanced control and monitoring capabilities. The PAT that was 
implemented into the system included a particle size analyzer (Chapter 5) and a near-infrared 
(NIR) sensor (Chapter 6). The particle size analyzer took at-line measurements and provided 
information such as mean particle size and particle size distribution. The NIR sensor was placed 
within the concentrating stage process loop and was used to determine the total lipid 
concentration.  
 
To control the lipid concentration, a control loop (Fig. 3.3) was designed that used both feedback 
and feedforward control. The feedback control consisted of a pump that adjusts to maintain a set 
flow rate and was used to increase or maintain the lipid concentration. The particle size analyzer 
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and NIR sensor were both used as feedforward controls in that these measurements were inputs 
to a predictive model that is used to determine the lipid concentration.  
 
3.2.3.1 Particle Size Analysis 
There are many approaches to determine the particle size distribution of liposomes. Since the 
liposomes in this work are less than 1000 nm, techniques based on macroscopic fitting methods 
were only considered. These techniques include dynamic light scattering48-49, acoustic 
spectroscopy50, electron microscopy51-52, x-ray scattering53-54, etc. Since the process needs to be 
implemented into a continuous process, the list of techniques was narrowed down to dynamic 
light scattering and acoustic spectroscopy. Both techniques are suitable to measure the full range 
of the liposomes being analyzed (i.e. 25 nm up to ~500nm) and both techniques have the ability 
to measure concentrated samples (refer to chapter 6 for a comparison between each measurement 
technique). For on-line or at-line measurements, one difference between the two techniques is 
that dynamic light scattering requires either very low flow rates (~1 mL/min) or static conditions 
(no flow) for accurate measurements whereas acoustic spectroscopy can provide measurements 
at higher flow rates. A second difference was related to the companies that manufactured these 
instruments. For the implementation and use as PAT, the particle sizing data would need to be 
accessible with the custom computer program written in NI LabVIEW. The company of the 
acoustic spectroscopy device did not provide a direct means to communicate with NI LabVIEW. 
However, the company that supplied the dynamic light scattering instrument provided an option 
with direct communication via an open platform communications (OPC) client/server. For this 
reason, dynamic light scattering was chosen as the instrument of choice. 
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A risk analysis was outlined for the particle size analysis (Fig. 3.4). The effect/outcome of this 
diagram was the accurate measurement of particle sizing data for a continuous process. The 
causes were subdivided into flow conditions, flow cell and DLS measurement. The flow 
conditions outlined how to control the flow of the sample to the instrument (e.g. pump selection) 
and flow requirements (e.g. continuous and laminar flow vs. stopped flow). The flow cell has 
limitations such as the total volume of the flow cell and the pressure rating, which would limit 
the flow rate of the sample through the flow cell. Lastly, DLS measurement parameters will 
further impact the accuracy of particle sizing data. These parameters include temperature, 
measurement duration (e.g. 10 seconds), number of runs per measurement and the attenuation 
setting. As DLS uses a macroscopic fitting algorithm to determine the particle size, the sample 
temperature and photon count rate will impact the particle size analysis. For example, if the 
temperature is set at 25°C, but the sample temperature is actually 22°C, then the measured 
particle size may be higher than actual since particles move more slowly at lower temperatures 
than higher temperatures. In this case, the set temperature and the actual sample temperature 
must be similar to achieve accurate results. As a second example, the photon count rate is the 
rate at which photons are detected. For low count rates, there is not enough information for the 
macroscopic fitting algorithm to determine the particle size. In addition, at higher count rates, the 
DLS detector may no longer be operating in a linear range. Therefore, a range of count rates 
should be determined that provide accurate data.  
 
3.2.3.2 NIR Turbidity Sensor 
A NIR sensor was implemented into the process as a means to determine the concentration of the 
liposome sample. A NIR sensor has the ability to detect turbidity changes and these changes can 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
31 
 
be related to the lipid concentration via an algorithm. Rayleigh scattering is proportional to the 
sixth power of the particle diameter; therefore, larger particles scatter more light. It was then 
hypothesized that for a known particle size, the concentration of the liposomes could be 
determined (Chapter 6). A risk analysis diagram outlines possible factors that will influence 
concentration detection via a NIR sensor (Fig. 3.5). For instance, there are a two common NIR 
sensor styles, i.e. a probe design or a flow cell design. The probe design may be more prone to 
air bubble accumulations at the detection window. In addition, the probe design may have a 
limited optical path length (e.g. up to only 10 mm), whereas the flow cell design may have 
longer optical paths (e.g. up to 160 mm). The longer optical path would accommodate samples 
that scatter a small amount of light (i.e. smaller diameter particles at low concentrations). In 
addition, NIR probes may be designed at a single wavelength or a band of wavelengths and at 
various angles of detection. For angles of detection that are 0° from the light source, the 
measurement is referred to as absorbance and measured in units such as CU. Scattered light may 
be detected at angles such as 11° or 90°. For the scattered light, the unscattered light is used as a 
reference to account for changes in the aqueous medium. 
 
3.2.4 Material and Process Parameters on Particle Size Formation 
There are many material properties in conjunction with process parameters that are thought to 
influence the formation of liposomes. These material and process parameters are outlined in the 
cause and effect diagram from Fig. 3.6. The causes are divided into process variables, material 
variables and lipid molar ratio. The process variables includes types of flow (e.g. laminar vs. 
turbulent), type of pump (e.g. pulsatile vs. non-pulsatile) and Reynolds number. The Reynolds 
number is a means to determine the extent of mixing – with a higher Reynolds number indicating 
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a greater extent of mixing. The Reynolds number is dependent on viscosity, temperature and 
flow velocities. The material variables are subdivided into type of lipid and aqueous phase. The 
type of lipid will significantly impact the liposome particle size. For example, each lipid has a 
transition temperature, which indicates the fluidity of the lipid at a certain temperature. Lipids 
that may be in the fluid state could possibly form larger liposomes; however, this is not clearly 
understood at this time. The lipid molar ratio is another cause that my affect the liposome 
particle size. As many liposomal formulations consist of multiple lipids, the combination of the 
lipids must result in a packing parameter that supports the lamellar structure; otherwise, 
liposomes will not form. Therefore, the lipid ratio of, for example, cholesterol and other lipids 
must equate to approximately 1 in order to support a lamellar phase – which is the phase that will 
form liposomes.  
3.3 Conclusion 
The quality by design approach was implemented at the onset of this work and a risk analysis 
was the initial tool used in this approach. A risk analysis is an important tool for determining 
critical material and processing parameters than can affect a specific outcome. A risk analysis 
was outlined for each processing stage, the implementation of PAT and for the formation of 
liposomes.  
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3.4 Figures 
 
 
 
 
Fig. 3.1 A risk assessment comparing two processing techniques to make liposomes with the 
intention to develop the current process into a continuous process. 
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Fig 3.2: A cause and effect diagram highlighting the main stages of the continuous process with 
subdivisions for each main stage. 
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Fig 3.3: The control design for the concentrating system. This design uses feedback control 
(pump flow rate) and feedforward control (particle size analyzer and an NIR sensor) to determine 
the lipid concentration. The particle size data and data from the NIR sensor are incorporated into 
a mathematical model used to predict the lipid concentration. 
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Fig 3.4: A cause and effect diagram outlining variables that result in obtaining accurate particle 
size data for a continuous process. 
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Fig 3.5: A cause and effect diagram outlining variables that affect the lipid concentration 
detection via a NIR sensor. 
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Fig 3.6: A cause and effect diagram outlining variables that affect the liposome formation 
process with respect to material and process variables. 
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Chapter 4 
 
Liposome Formation using a Coaxial Turbulent Jet in Co-Flow 
4.1 Abstract  
Liposomes are robust drug delivery systems that have been developed into FDA-approved drug 
products for several pharmaceutical indications. Direct control in producing liposomes of a 
particular particle size and particle size distribution is extremely important since liposome size 
may impact cellular uptake and biodistribution. A device consisting of an injection-port was 
fabricated to form a coaxial turbulent jet in co-flow that produces liposomes via the ethanol 
injection method. By altering the injection-port dimensions and flow rates, a fluid flow profile 
(i.e. flow velocity ratio vs. Reynolds number) was plotted and associated with the polydispersity 
index of liposomes. Certain flow conditions produced unilamellar, monodispersed liposomes and 
the mean particle size was controllable from 25 nm up to >465 nm. The mean liposome size is 
highly dependent on the Reynolds number of the mixed ethanol/aqueous phase and independent 
of the flow velocity ratio. The significance of this work is that the Reynolds number is predictive 
of the liposome particle size, independent of the injection-port dimensions. In addition, a new 
model describing liposome formation is outlined. The significance of the model is that it relates 
fluid dynamic properties and lipid-molecule physical properties to the final liposome size. 
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4.2 Abbreviations 
Reynolds Number – Re 
Flow Velocity Ratio – FVR 
Dynamic Light Scattering - DLS 
Polydispersity Index - PDI 
Design of Experiment - DOE 
31 Phosphorous Nuclear Magnetic Resonance - 31P-NMR 
1,2-dimyristoyl-sn-glycero-3-phosphocholine - DMPC  
1,2-dipalmitoyl-sn-glycero-3-phosphocholine - DPPC 
1,2-distearoyl-sn-glycero-3-phosphocholine - DSPC 
1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) - DPPG 
1,2-dioleoyl-sn-glycero-3-phosphocholine – DOPC 
Cholesterol – Chol 
Negative Stain Transmission Electron Microscopy – NS-TEM 
Cryogenic Transmission Electron Microscopy – Cryo-TEM 
National Instruments – NI 
International Conference on Harmonisation – ICH 
Process Analytical Technology - PAT 
Combined Output Flow Rate – Q 
Kinematic Viscosity – v 
Diameter – D 
Outer Diameter – OD 
Inner Diameter - ID 
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Cross-Sectional Area – A 
4.3 Introduction 
The ethanol injection method is a well-known liposome preparation method.46 This method 
consists of dissolving lipid in ethanol (or a water-miscible organic solvent) and subsequently 
injecting this solution into an aqueous phase. Under certain conditions (e.g. at a low lipid 
concentration and processing lipids in the fluid state), the result is a dispersion of liposomes. The 
ethanol injection method offers the following advantages over other liposome preparation 
techniques: (1) the possibility to use ICH class 3 residual solvents rather than more toxic ICH 
class 2 solvents normally used in the thin-film hydration method (i.e. chloroform)55; (2) precise 
control over particle size and particle size distribution; (3) the avoidance of additional 
downsizing techniques such as sonication and/or extrusion; and (4) this process is a naturally 
continuous process. The latter is of high importance since it is of current interest to implement 
continuous processing in the pharmaceutical industry36, 56 . Continuous processing introduces 
many benefits over batch processing. For instance, the process run-time determines the final 
amount of product manufactured, not the size of the reactor. Therefore, the numerous issues 
related to process scalability may be lessened or avoided when progressing through clinical trials 
to large-scale manufacturing. In addition, continuous processing may be automated, which 
reduces human involvement and error. An important feature of continuous processing is the 
ready implementation of process analytical technology (PAT) that further enhances the overall 
control of the system36. The implementation of PAT reduces energy usage, product waste and 
ultimately leads to a higher quality product.  
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There have been a number of recent reports on using the ethanol (or alcohol) injection process 
for the preparation of unilamellar liposomes57-60. There are two fundamentally different fluid 
mixing schemes to form monodispersed liposomes using this technique. The first scheme is 
based on molecular diffusion where the alcohol is hydrodynamically focused into the aqueous 
phase.61 In this case, microfluidics devices are required to prepare liposomes under laminar 
conditions with a low Reynolds number (Re, where Re <<100)62. Such liposome formation 
appears to take place on the edges of the alcohol/aqueous flow streams as water slowly mixes 
with the alcohol phase63. The second scheme is based on inertial convective mixing or rapid 
mixing of the alcohol stream with the aqueous streams. This scheme has been demonstrated by 
creating a turbulent liquid jet either in co-flow (with the aqueous phase)59 or in cross-flow 
(angled to the aqueous phase)57. Moreover, flow conditions based on this approach typically 
operate at a higher Re from 100 to >3000.  
 
In the current work, liposomes were prepared using a coaxial turbulent jet in co-flow. The 
liposome formation process was investigated by relating fluid dynamic properties and lipid 
properties to liposomal physical properties. More specifically, it was hypothesized that under 
certain processing conditions, altered fluid flow profiles (e.g. changing volumetric flow rates to 
increase/decrease the Reynolds Number)  combined with formulation properties (e.g. lipid type, 
hydrocarbon tail saturation, and aqueous phase additives) would result in the prediction of 
liposomal physical properties (e.g. mean particle size). In addition, a new model based on lipid 
hydrocarbon tail length, hydrocarbon saturation and aqueous phase additives was outlined that 
explains the liposome formation process using a turbulent jet in co-flow. 
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4.4 Materials and Methods 
4.4.1. Overview of Process with Turbulent Mixer 
Liposomes were prepared by a modified ethanol injection method. A schematic of this system is 
demonstrated in Fig. 1. Three separate 316 stainless steel tanks were fabricated to house the 
lipid+ethanol solution. These tanks were pressurized (at typically 20 psi) and the flow rates from 
these tanks were controlled by analog flow meters (McMillian) and proportioning solenoid 
valves (Aalborg). The flow meters were factory calibrated for water with less than 1% error. For 
the lipid+ethanol flow streams, these flow sensors were re-calibrated for ethanol and had an R-
squared value of 0.9989, with a working range from 5-50 mL/min. The three tanks were then 
connected at a single point using a 4-way connector (Swagelok). A static mixer was 
implemented to ensure that the lipid+ethanol solutions from the three tanks were adequately 
mixed prior to reaching the injection port where the ethanol and aqueous streams converged. The 
aqueous phase volumetric flow rate was controlled by a gear pump (Micropump®). The mixed 
lipid+ethanol solution was then injected into the aqueous phase at various flow rates. The tubing 
ID of the ethanol phase was 0.508 or 1.016 mm (1.588 mm OD). The aqueous phase tubing ID 
was fixed at 3.175 or 4.572 mm. Typical flow rates of the lipid+ethanol phase were from 5-40 
mL/min and of the aqueous phase were from 60-400 mL/min.  
 
The entire process was controlled by a custom-made program written using National Instruments 
(NI) LabVIEW® software. A data acquisition system (NI PXIe-1078) was combined with 
multiple NI modules to accommodate various input/output signals (e.g. analog and digital 
inputs/outputs, counters, circuit switches, etc.).  The entire system was automated and only 
required the user to define the final lipid concentration and molar ratios of lipid. Process 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
44 
 
variables such as flow rates, pressure, and temperature were monitored and, for some variables, 
automatically adjusted using custom computer algorithms. For example, proportional-integral-
derivative controls were implemented in the computer program to precisely control the flow rates 
of both the ethanol and aqueous phases.  
 
4.4.2. Liposome Preparation  
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-
sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) (DPPG) and 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), were purchased from Lipoid™. Cholesterol (Chol) was purchased 
from Sigma. The lipid (5-30 mM total lipid) was dissolved in ethanol (USP grade) and added to 
one of the three tanks. To dissolve the lipid in ethanol, the lipid mixture was typically heated to 
60°C for 10 minutes and sonicated for 5 minutes or until all of the lipid was fully dissolved. The 
ethanol solution was then allowed to reach room temperature (23°C) prior to running any 
experiment. In some cases, the entire lipid was combined into a single tank and pure ethanol was 
added to the other tanks for dilution. 
 
4.4.3 Dynamic Light Scattering for Particle Size and Zeta-Potential 
Measurements were performed with a Malvern Zetasizer Nano ZS90 for zeta potential and a 
Malvern Zetasizer Nano S for size. The samples were placed in plastic disposable cuvettes (or a 
capillary cell for zeta-potential) and equilibrated to 25°C prior to measurements. Since ethanol 
was present in the samples, all samples were diluted to 1.64% v/v (ethanol/total solution) and the 
viscosity and refractive index were adjusted for in the Malvern Zetasizer software. Particle size 
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measurements included the z-average, PDI, volume percentage, intensity mean and intensity 
width. Zeta potential measurements included zeta-potential and zeta deviation. All measurements 
were run in triplicate. 
 
4.4.4 Flow Visualizations 
Nile Red (Sigma-Aldrich®) was used as the dye and was dissolved in ethanol. This solution was 
added to one of the three pressure tanks. Lipid dissolved in ethanol was added to a second tank. 
The lipid and Nile Red solutions were run at a 1:1 volumetric ratio under different flow 
conditions. As Nile Red changes color based on solution polarity64, the solution appeared pink in 
ethanol, pink/orange with lipid dissolved in ethanol and purple/bluish when dissolved or mixed 
with water without lipid. 
 
4.4.5 Nanoparticle Tracking Analysis 
Measurements were performed with a Malvern Nanosight™ instrument. The samples were 
diluted down to 0.05% v/v ethanol. In some cases, additional dilution was necessary to reach 
acceptable conditions for particle size analysis (e.g. as vesicle diameter decreases, the number of 
vesicles increased exponentially). As for the measurements, the mean and standard deviation 
were recorded. All measurements were run in triplicate. 
 
4.4.6 Negative Stain Transmission Electron Microscopy (NS-TEM) 
 Liposomes were prepared in 10 mM ammonium acetate-acetic acid buffer at pH 5.00. For each 
sample, approximately 3 µl of liposomes was placed on a plasma cleaned carbon coated grid 
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(Ted Pella Inc, #01840).  After 1 minute incubation, the sample was flooded with several drops 
of 0.25% of uranyl acetate stain. The excess solution was blotted off and the sample was air 
dried for approximately 30 minutes. The grid was imaged at 80.0 kV in an FEI Tecnai 12 
Biotwin TEM equipped with a LaB6 emitter and an Advanced Microscopy Techniques 2k XR40 
CCD camera. For each sample, 7-10 images were collected and the diameter of more than 500 
particles/sample were manually measured using ImageJ. The data was then collected and the 
mean particle size and standard deviations were determined by fitting a nonlinear analysis using 
a Gaussian distribution fitting function. 
 
4.4.7 Cryo-Transmission Electron Microscopy (cryo-TEM) 
 Cryo-TEM was performed using cryo-transmission electron microscopy (Jeol 1400 
TEM/STEM) operated at 120 kV and viewed under the Minimum Dose System. Briefly, 2 µL of 
liposome sample was placed on a glow-discharged Holey carbon copper grid (Quantifoil R 2/1). 
Using a grid plunge freezer (Leica EM GP) at 25 °C and 82% humidity, samples were blotted 
automatically for 2 s to remove excess liquid and plunged into a bath of liquid ethane at −175 °C. 
The samples were stored in liquid nitrogen until they were transferred to a cryo-TEM holder 
(Gatan 914) and observed in the pre-cooled cryo-TEM at 120 kV under Minimum Dose System. 
Images were recorded with a digital CCD Camera (Gatan ORIUS™ SC1000) at magnification of 
10000 x- 20,000x. 
 
4.4.8 Design of Experiment Study 
A design of experiment was performed to analyze the lipid concentration and aqueous phase 
flow rates on liposome particle size. The aqueous phase flow rate range was designed to cover a 
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broad range of flow conditions that led to low and high Reynolds Numbers (see “Reynolds 
Number and Flow Velocity Ratio Calculations”). In addition, these flow rates cover the full 
range of the system processing capabilities (i.e. pump flow rate working range). Lipid 
Concentrations studied were based on reported lipid wt% that would possibly lead to the 
formation of liposomes65. A custom 2x4 full factorial design with 5 center-points, and 3 repeats 
was chosen as the initial design (Fig. 2). This design was chosen to support interaction and 
higher order terms as well as stay within constraints on the final ethanol percentage. The original 
design was augmented to increase the design space and to increase the statistical significance of 
the model (Fig. 2). With respect to model analysis, the r-squared term, analysis of variance 
(p<0.05) and lack of fit p-value (p>>0.05) were used to determine adequate fitting and the 
inclusion of model interaction terms. Only the Malvern Zetasizer Nano S was used to determine 
the particle size and PDI for this study. The model design and analysis was conducted using JMP 
by SAS. 
 
4.4.9 Reynolds Number and Flow Velocity Ratio Calculations 
The Reynolds number (Re) is defined as Re = QD/νA, where Q is the combined output flow rate, 
ν is the kinematic viscosity of the mixture, D is the diameter of the output tube and A is the 
cross-sectional area of the output tube. The kinematic viscosity was calculated for the final 
ethanol-water mixture based on reported dynamic viscosity and density values66. An equation 
was created using JMP by SAS to predict the kinematic viscosity with dependence on ethanol 
mole fraction and the output temperature (Supplemental Data Equation 1). As the enthalpy of 
mixing for water and ethanol mixtures is exothermic, the final output temperature varied from 
the initial temperatures of both phases (i.e. 23°C) up to ~32°C. These temperatures were 
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recorded for the various flow conditions and were used in the Re calculation. The flow velocity 
ratio (FVR) is FVR = vi/vo, where vi is the inner tube velocity and vo is the outer tube velocity. 
Both velocities are calculated directly from the volumetric flow rates and the geometry of the 
tube. For the outer tube velocity calculation, the inner tube outer diameter was subtracted from 
the outer tube inner diameter. 
4.5. Results 
4.5.1 Mixing of Ethanol and Aqueous Phase 
An injection port was fabricated to accommodate the formation of a coaxial turbulent jet in co-
flow. A cylindrical tube (inner tube) designed to carry the ethanol phase was positioned 
concentrically within second or outer cylindrical tube (Fig. 3). The second cylindrical tube (outer 
tube) carries the aqueous phase prior to jet formation.  There are three criteria necessary to 
achieve suitable conditions for a stable turbulent jet. The first is that all flow rates must be 
pulseless to reduce flow rate fluctuations to negligible levels. The second two criteria come from 
non-dimensional values of fluid dynamics: (1) Reynolds number (Re) and (2) flow velocity ratio 
(FVR). The Re is that of the mixed ethanol/aqueous flow stream just downstream of the “jet 
location” (in Fig. 3) and will subsequently be referred to as the Remixture.  
 
4.5.2 Relationship between Fluid Flow Properties and Liposomal Polydispersity Index 
The fluid flow properties of the injection-port were related to the liposome polydispersity index. 
Liposomes were analyzed using dynamic light scattering (DLS) and a polydispersity index (PDI) 
of 0.10 was considered as the upper limit for monodispersity. The ethanol flow rate ranged from 
5-40 mL/min and the aqueous phase flow rate ranged from 70-400 mL/min. The organic phase 
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consisted of DPPC:DPPG:Chol (4.5:0.4:3 molar ratio) dissolved in ethanol and the aqueous 
phase was 10 mM phosphate buffer, pH 7.4. The inner tube diameter was 0.508 mm or 1.016 
mm. The outer tube diameter was 3.175 mm or 4.572 mm. In addition, the maximum final 
ethanol percentage was chosen to be less than 40% v/v ethanol to reduce the possibility of 
forming any non-liposomal structures65. For this lipid formulation, the average zeta-potential was 
-39.4 ± 6.34 mV (averaged for all samples). 
 
The flow rates were transformed to Remixture and FVR as outlined in the methods section. To 
achieve various Remixture and FVR combinations, different inner and outer tube diameters were 
investigated. From Fig. 4a, it is clear that in order to achieve a monodispersed system, certain 
Remixture and FVR combinations are required to form a stable jet. Fig. 4b depicts the fluid profiles 
of four locations on the FVR vs. Remixture plot from Fig. 4a. At a Remixture < 500 and FVR < 7, a 
stratified flow is observed with the lipid+ethanol staying separated and moving to the top of the 
tubing (Fig. 4b-1). Limited mixing occurs in this case and the actual lipid mixing/liposome 
formation would occur downstream (i.e. possibly in the collection vessel) – leading to 
polydispersed liposomes. At FVR ≤ 2 and Remixture >~ 500, a weak jet forms and this also leads to 
polydispersed liposomes (Fig. 4b-2). The other two flow conditions depicted lead to rapid 
mixing downstream of the injection site and stable jet formation, resulting in monodispersed 
liposomes (Fig. 4b-3 and Fig. 4b-4). In the case monodispersed liposomes, it is evident that 
liposome formation is primarily dependent on mixing and can be predicted by the Remixture (Fig. 
4c). At a high FVR (i.e. ≥ 7), the liposome particle size is monodispersed and independent of 
FVR and only changes according to the Remixture. The latter case outlines that monodispersed 
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liposomes may be formed under a variety of injection port dimensions that lead to the same FVR 
and Remixture conditions. 
 
4.5.3 Design of Experiment: Lipid Concentration vs. Particle Size 
A design of experiment (DOE) study was completed to demonstrate the effects of the injected 
lipid concentration on liposomal particle size for a monodispersed population of liposomes. The 
ethanol flow rate was fixed at 40 mL/min as this flow rate corresponding to a flow region that 
produces monodispersed particles (Fig. 4a). The dimensions of the injection port were fixed at an 
aqueous phase tubing ID of 3.175 mm and an ethanol phase tubing ID of 0.508 mm. For the 
DOE study, the factors included: (1) aqueous phase flow rate (70-400 mL/min) and (2) injected 
lipid concentration (5-30 mM). The aqueous phase was 10 mM phosphate buffer. The lipid 
composition was fixed at DPPC:DPPG:Chol (4.5:0.4:3 molar ratio). The DOE model has a R2-
value of the actual vs. predicted values of 0.985, an analysis of variance p-value <0.0001 and a 
lack-of-fit p-value = 0.331 (Table I). The surface profile for this study clearly demonstrates the 
dependence of the mean particle size on the aqueous phase flow rate (Fig. 5). For this 
formulation, the smallest liposomes appeared around 58 nm and the largest around 240 nm. The 
PDI value averaged 0.05 ± 0.04 for all experiments, and only started to reach 0.10 at the lower 
aqueous phase flow rates (e.g. 70 mL/min). Thus, the liposomes could be considered 
monodispersed over the entire range of flow rates studied. The lipid concentration had a modest 
positive impact on the particle size. It was apparent that the aqueous phase flow rate interaction 
terms were dominant in controlling the z-average liposome particle size. 
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4.5.4 Types of Lipid on Liposome Particle Size 
From the results above, it is clear that the Remixture and lipid concentration play an important role 
in controlling liposome particle size. To determine whether lipid characteristics affect liposome 
particle size, four different lipid molecules were investigated, namely DOPC, DMPC, DPPC, 
DSPC and a mixture of DPPC:DSPC (1:1 molar ratio). Each formulation also contained 
cholesterol and DPPG. The molar ratio was held constant for lipid:DPPG:Chol (4.5:0.4:3.0) and 
5 mM total lipid was dissolved in the ethanol phase. The z-average particle size and PDI values 
are plotted (Fig. 4.6). It is clear that the lipid molecule significantly altered the liposome particle 
size. Liposomes with a mean particle size were controllably formed from approximately 25 nm 
up to 465 nm and the maximum PDI value was equal to 0.18; however, the PDI was ≤ 0.05 for 
the majority of the samples (Fig. 4.6). 
 
4.5.5 Aqueous Phase Additives on Liposome Particle Size 
Additives to the aqueous phase were used to determine any impact on liposome formation. For 
this study, the lipid formulation was kept constant at DPPC:DPPG:Chol (4.5:0.4:3 molar ratio, 5 
mM lipid injected) and all samples contained 10 mM phosphate buffer, pH 7.4. NaCl; glycerol; 
and ethanol were investigated as additives (Fig. 7). Liposomes prepared in 10 mM phosphate 
buffer with no additive was used as a control. For all flow conditions, the formulation containing 
26 wt% glycerol was the most similar to the control. The addition of 10-30% v/v ethanol to the 
aqueous phase increased the particle size under most flow conditions. The 30% v/v ethanol 
addition caused the liposomes to be linearly dependent on the aqueous phase flow rate. The 
addition of 0.9 wt% NaCl dramatically increased the mean particle size under all conditions 
compared to the control. 
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4.5.6 Comparison of Particle Size and Size Distribution using Multiple Measurement 
Techniques 
To accurately assess the mean particle size and particle size distribution, multiple techniques (i.e. 
dynamic light scattering, nanoparticle tracking and negative stain TEM) were used. Each of the 
three techniques can be used to determine the mean particle size and particle size distribution; 
however, each technique differs fundamentally. Dynamic light scattering is an intensity-based 
measurement, while nanoparticle tracking and negative stain TEM are number-based. Therefore, 
it is not desired to compare absolute values from each technique, but instead to compare trends 
and conclude if monomodal populations of particles are present. Samples were prepared in 10 
mM ammonium-acetate-acetic acid buffer at pH=5.0 to reduce artifacts in the negative staining 
procedure. The lipid composition for this study was DMPC:Chol:DPPG (4.5:3.0:0.4 molar ratio) 
and 15 mM lipid was injected into the aqueous phase. Three samples were prepared at a constant 
ethanol flow rate (40 mL/min) but at different aqueous phase flow rates (i.e. 100, 150 and 375 
mL/min). The three samples were chosen as they were estimated to produce liposomes with a 
mean particle size around 350, 140 and 70 nm, respectively (Fig. 6). Fig. 8 displays the mean 
particle size data from the three separate techniques. It is clear that nanoparticle tracking and 
dynamic light scattering display a monodispersed population. Negative staining produces an 
overall wider distribution of particles and possibly smaller particles present in the larger-sized 
liposome sample. However, the negative stain TEM results may not adequately represent the 
liposome population due to a low number count and multiple artifacts that can occur during 
sample preparation. Fig. 9 is a plot of the mean particle size and the standard deviation for each 
sample and technique. Most importantly, it was demonstrated that the mean particle size trend is 
the same using all three particle sizing techniques, i.e. for an increase in aqueous flow rates 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
53 
 
(higher Remixture), the particle size decreases. For all three samples and each particle size analysis 
technique, the standard deviations were 15.8 ± 4.70% of the mean. 
 
4.5.7 Negative Stain TEM Micrographs of Liposomes 
Fig. 10 (a-c) are micrographs of the three different samples outlined above (Fig. 8) from the 
particle size technique analysis. The micrographs clearly demonstrate particle size differences 
between samples. Each sample set appears to be monodispersed. Fig. 10d demonstrates how 
liposomes are affected by the staining process. It appears that the liposomes are in one of three 
possible states: (1) “partially-hydrated” liposomes (these liposomes appear to be dehydrated, but 
partially retain the structure as in the hydrated state); (2) flattened-stacked bilayers; or (3) 
mixture of a flattened-stacked bilayer and/or single bilayer. The “partially- hydrated” liposomes 
have an appearance of dehydrated liposomes and have more uniform size, while the “flattened” 
states vary in size. This apparent size variation (that results from the processing required for this 
technique) can explain why the mean particle size and size distribution are overall greater from 
the NS-TEM micrographs compared to the other particle size analysis techniques. 
 
4.5.8 Cryo-TEM Micrographs of Liposomes 
The micrographs from Fig. 11 (a-c) are of the three different samples outlined above in Fig. 8 
and Fig. 10. These micrographs confirm the particle size trend stated previously and that these 
liposomes are unilamellar. Comparing the visible black band of each liposome, the thickness of 
the band is very similar for the small to the large liposomes. 
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4.6 Discussion 
4.6.1 Liposome Monodispersity via a Coaxial Turbulent Jet 
Flow conditions, characterized by the FVR and the Remixture, lead to either polydispersed or 
monodispersed liposomes (Fig. 4a). Polydispersed liposomes were formed under two different 
flow conditions – i.e. an apparent stratified flow (Fig. 4b-1) and a weak jet (Fig. 4b-2). The 
stratified flow led to stream separation and uncontrolled mixing. The weak jet appeared to 
develop vortices that led to backflow along the jet – also resulting in uncontrolled mixing.  
 
In order to achieve monodispersed liposomes, the formation of a jet was required (Fig. 3). 
Depending on the flow conditions, it appeared that there was the coexistence of a 
laminar/transitional flow followed by a jet that led to turbulent flow (Fig. 4b-3 and Fig. 4b-4). 
For a similar set of Reynolds numbers, Kwon et al. observed the same effect of a decrease in the 
laminar/transitional region with an increase in the Re67. It does not appear that the aqueous phase 
significantly dilutes the ethanol phase in this laminar/transitional flow region; otherwise, a color 
change in the fluorescent marker (Nile Red) would be observed due to the change in fluid 
polarity64. Accordingly, it may be stated that limited mixing occurs throughout the 
laminar/transition region. For the formation of a jet, it has been shown that the center velocity 
decreases68 and the jet boundary spreads radially, resulting in a concentration gradient69 of the 
injected phase (in this case, lipid+ethanol). Therefore, the majority of mixing occurs where the 
center velocity decreases and jet boundary spreads radially. As the spreading of the lipid+ethanol 
phase establishes a radial concentration gradient, it is proposed here that this promotes the 
controlled formation of monodispersed liposomes. Moreover, convective inertial forces are 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
55 
 
dominant compared to viscous forces when Re >>1, which supports the reasoning that increasing 
Re will correspond to an increase in the extent of mixing, thus forming different sized liposomes.  
For the formation of monodispersed liposomes, it is clear that Remixture is directly related to the 
liposome particle size. In addition, above a FVR of approximately 7, liposome formation is 
independent of FVR and dependent only on the Remixture. This observation is made by comparing 
Fig 4a with Fig 4c, where the liposomes formed at the same Remixture have a similar particle size, 
regardless of the FVR. This latter statement is highly significant because it outlines that liposome 
formation from a turbulent jet is predominately a convective process and occurs at the radial 
spreading in the turbulent region of the jet.  
 
Considering the phospholipid formulation as well as the Remixture and FVR, the formulations 
containing DSPC, DPPC and DMPC formed mostly monodispersed liposomes (for an FVR ≥ 7). 
Some polydispersity was evident at lower aqueous flow rates and may have been due to higher 
ethanol percentages destabilizing the liposomes. However, the formulation containing DOPC 
formed only monodispersed liposomes at the lower aqueous flow rates. For DOPC, a higher 
Remixture appears to destabilize the formulation, which could be due to the high curvature of the 
small particles (~25nm) and/or the low phase transition temperature of DOPC – making the fluid 
bilayer more susceptible to fusion at ambient temperature conditions. 
 
4.6.2 Liposome Formation Model using a Coaxial Turbulent Jet 
The injection of lipid dissolved in ethanol into an aqueous phase is further complicated by 
changes in properties such as viscosity66, density66, molar volume66, heat of mixing (exothermic 
in this case)70, lipid solubility65, and lipid structure (e.g. lipid molecular volume). It does not 
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appear that any property above is solely related to the observed particle size changes of 
liposomes. By using the Remixture, the following terms are taken into account: viscosity, density 
and sensible heat gains. 
 
The exact mechanism of how liposomes form is still elusive; however, a detailed model for the 
liposome formation process is beginning to emerge through experimental findings. The idea of 
mixing lipid dissolved in a water miscible solvent and injected into an aqueous phase has been 
around since the early 1970s.46 Initial work in this field has outlined that bilayered phospholipid 
fragments (BPF)71 form and fuse together as the volume percentage of ethanol decreases. For a 
turbulent jet, a model based on the formation and subsequent fusion of BPF resulting in 
monodispersed liposomes leads to some doubt. During the centerline velocity dissipation of a jet, 
multiple vortices form and subsequently shear off. Since this process is turbulent, vortices of 
different sizes would develop and the mixing in these micro-environments would appear to be 
heterogeneous.  Consequently, BPFs that fused during this process would only form 
polydispersed particles.  
 
A new model for liposome formation is proposed (Fig. 4.12). This model is based on the growth 
of a highly fluid lipid/ethanol aggregate (denoted here as a pro-liposome). Initially, lipid is 
dissolved in ethanol forming a solution. As outlined above, the ethanol spreads radially at the jet 
location resulting in a concentration gradient. At this point, water mixes with the ethanol+lipid 
phase and pro-liposomes begin to grow in size until a critical solubility is reached (~50-60% v/v 
ethanol). The final liposome size is then dependent on the following factors: (1) ethanol diffusion 
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out of the pro-liposome, (2) pro-liposome fluidity, (3) lipid packing, (4) pro-liposome surface 
charge and (5) lipid concentration.  
 
Ethanol diffusion out of the pro-liposomes is exemplified by the addition of excess ethanol to the 
aqueous phase. Ethanol is known to be able to cross the lipid bilayer, i.e. move from the aqueous 
phase into one bilayer leaflet and cross from one leaflet to the other72. In addition, 31P-NMR 
studies have confirmed that ethanol causes the liposome bilayer to become less packed.73 
Comparing 10-30% v/v excess ethanol to 0% v/v excess ethanol in the aqueous phase, ethanol 
diffusion out of the pro-liposome would be slower during the mixing process and consequently 
the bilayer would have higher permeability due to the larger amount of ethanol. Accordingly, 
there would be more time and space for lipid molecules to enter the pro-liposome – thus growing 
in size. Moreover, the addition of 26 wt% glycerin to the aqueous phase did not cause any major 
change in particle size, which indicates that the increased bulk viscosity is less essential 
compared to ethanol diffusion out of the pro-liposome and convective forces. 
 
The lipid phase transition is important in assessing the fluidity of the pro-liposome. The phase 
transition temperatures of the phospholipids in this study are ranked in the following order: 
DSPC>DPPC>DMPC>DOPC (highest to lowest)74. By comparing only the saturated 
phospholipids, DSPC is the most ordered while DMPC is the most fluid over the temperature 
range caused by exothermic mixing in these experiments (i.e. 23-32°C). It appears that liposomes 
form when lipid molecules are in the fluid/disordered state rather than the gel/ordered state. For 
example, DPPC:DPPG (7.5:0.4 molar ratio) formed a viscous, gel-like structure instead of 
liposomes at a 5mM lipid injection (data not shown). It should be noted that adding cholesterol 
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increases the fluidity/disorder of the lipid membrane; thus, making it is possible to form 
liposomes at temperatures below the lipid phase transition temperature of the corresponding pure 
lipid. A more ordered structure would prevent lipid molecules from entering the pro-liposome – 
resulting in smaller liposomes. This reasoning explains why liposomes form in the following 
order of smallest to largest (DSPC<DPPC<DMPC). A more detailed analysis that includes the 
impact of temperature, cholesterol percentage and charged lipid percentage may be useful to 
thoroughly explain the above observation. 
 
Changes in lipid packing are exemplified by DOPC, which adds an additional complexity in that 
this lipid is unsaturated (i.e. it has a double bond in each hydrocarbon tail). The geometric 
packing parameter of DOPC75 is = 1.08 and, when mixed with other lipids, may support a 
geometrically smaller sized particle (i.e. as low as 25 nm in diameter). In comparison, DSPC, 
DPPC, and DMPC lipid molecules have a packing parameter ~1 and are more cylindrical in 
shape. Thus, these DOPC liposomes can support higher curvature/ smaller sized liposomes than 
DSPC even though the phase transition temperature of DOPC was much lower relative to the 
experimental conditions. Moreover, the more cylindrical shape of DSPC, DPPC and DMPC may 
explain why these liposomes appear to plateau at a mean particle size of ~60-70nm at a high 
Remixture. This indicates that the overall lipid packing of the lipid mixture is a geometric 
constraint on the liposome particle size.  
 
In the case of the surface charge, the addition of salt to the aqueous phase (e.g. 0.9 wt% NaCl) 
would lower the surface charge of the pro-liposome and lessen the electrostatic repulsion 
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between the pro-liposome and the individual lipid molecules. This reduced repulsion would 
allow more lipid molecules to enter the pro-liposomes, thus increasing the final liposome size.  
Lastly, the lipid concentration led to a modest increase in liposome particle size. This increase in 
size further supports the pro-liposome model as more lipid molecules would be recruited into the 
pro-liposomes. It should be noted that only 5-30 mM lipid was injected, which is a relatively 
small amount of lipid compared to the other components in the system. Therefore, increasing the 
lipid concentration would be expected to increase the number of liposomes instead of 
proportionally increasing the size of the liposomes. Moreover, too high of an injection lipid 
concentration may cause other types of structures to form (e.g. stacked bilayers) and increased 
polydispersity76.  
 
Overall, the pro-liposome model appears to provide a clearer explanation on the liposome 
formation process using a turbulent jet. From the above discussion, Remixture can be used to 
predict the liposome particle size for a fixed set of factors (i.e. lipid type, lipid concentration, 
aqueous phase additives, etc.), but will not predict particle size when changing these factors. In 
addition, factors not studied here such as cholesterol percentage77, solvent/aqueous phase 
temperatures and type of solvent78 will also impact liposome formation and particle size. 
Therefore, additional studies will need to be performed using a turbulent jet in co-flow to build 
on the current liposome formation model. 
 
4.6.3 Particle Size Analysis using Multiple Measurement Techniques 
Dynamic light scattering is a suitable technique to determine monodispersity by analyzing 
multiple parameters. These parameters include the z-average, intensity mean, volume percentage 
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and the PDI. The z-average is calculated from a cumulants analysis (an intensity-weighted fitting 
algorithm) and the intensity mean is determined directly by an intensity fitting algorithm. When 
both the z-average and intensity mean values are very similar, it indicates that a single population 
is present. In addition, a volume percentage of 100% further points to a monodispersed system 
since transforming the data from intensity to volume shifts the emphasis away from the mean 
particle size. A volume percentage other than 100% may indicate the presence of additional 
populations of particles. However, there was an initial uncertainty in relying only on dynamic 
light scattering without comparing to other techniques, as the light intensity of any larger 
particles will overshadow the light intensity of smaller particles. This overshadowing may 
prevent the smaller particles from being detected, even when transforming the raw intensity data 
to a volume measurement.  
 
Comparing nanoparticle tracking and dynamic light scattering, both techniques appeared to show 
similar results with respect to mean particle size and size distribution. Since both of these 
techniques determine the particle size using completely different methods (i.e. individually 
tracking particles vs. fitting functions), the agreement in mean size and size distribution greatly 
supports that this liposome processing technique has the ability to controllably produce a large 
size range of monodispersed liposomes.  
 
The NS-TEM micrographs were originally obtained as a way to characterize the liposomes and 
possibly make visible smaller particle populations that dynamic light scattering might have failed 
to detect. After analyzing the TEM images, it was not possible to determine an accurate mean 
diameter or particle size distribution. One reason is due to the processing conditions apparently 
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causing multiple states of liposomes present (i.e. partially-hydrated to flattened stacked bilayers). 
A second reason is that what appears to be small particles may actually be fragments of larger 
particles. These possible fragments may explain why the nanoparticle tracking analysis via 
Nanosight, which analyzed 30,000-90,000 particles per sample, did not show a wider particle 
distribution and a possible second population of particles in the 40e:100a sample (Fig. 8).  
 
Lastly, the cryo-TEM micrographs further confirmed the mean particle size trend observed using 
the three particle size analysis techniques outlined above. The advantage of cryo-TEM over NS-
TEM is that the samples were controllably frozen to prevent ice-crystal damage and the 
liposomes were imaged in a more native state. In addition, these micrographs confirmed that the 
liposomes are unilamellar.  
4.7 Conclusion 
A turbulent jet mixer can be used to form unilamellar, monodispersed liposomes with a known 
particle size.  The unilamellar, monodispersed particles have a mean size anywhere from ~25 nm 
to >465 nm. The liposome mean particle size is highly dependent on the Remixture and is 
independent of the flow velocity ratios. The monodispersity and mean particle size trend of the 
liposomes was analyzed using three fundamentally different particle size analysis techniques. 
Dynamic light scattering and nanoparticle tracking demonstrated that the liposomes were 
monodispersed and increased in size with a decrease in Remixture. Lastly, a new model outlining 
the liposome formation process is explained via a pro-liposome growth model that takes into 
account aqueous phase additives, types of lipid molecules, and lipid concentration. 
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4.8 Tables 
Table 4.1 DOE on Lipid Concentration vs. Particle Size - Model Parameter Estimates Sorted by 
Statistical Significance1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1
 The aqueous phase flow rate (AFR) and the lipid concentration terms both have statistical 
significance. In addition, higher order AFR terms are required due to the non-linearity of the 
response (i.e. particle size). 
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4.9 Figures 
 
 
 
 
 
 
Fig. 4.1 Overall schematic of the lipid mixing process and the injection port (not shown to scale). 
Ethanol or lipid dissolved in ethanol is added to the pressurized tanks. NI LabVIEW is used to 
control the entire process and sensors such as flow meters are installed to control/monitor the 
flow conditions. 
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Fig. 4.2 The design space of the DOE study on the impact of lipid concentration and aqueous 
phase flow rate on particle size. The initial design consisted of 2 factors at 4-levels (black 
circles) and center points (red star). The design was augmented with additional runs to extend the 
model design space (blue triangles). 
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Fig. 4.3 Schematics and photographic image of the injection port that allows formation of a 
coaxial turbulent jet. Both the aqueous and ethanol streams are flowing in the same direction (co-
flow). Arrows indicate the direction of liquid flow. The photograph is of lipid dissolved in 
ethanol (visualized through the use of Nile Red) that is being injected in the center of the 
aqueous stream. Additionally, the jet location is shown as a schematic where there is a limited 
mixing zone followed by a concentration gradient of the ethanol+lipid phase.  
 
 
 
Fig. 4.4 Relationship between liposome polydispersity index and flow properties. 4a) Flow 
velocity ratio (FVR) vs. the mixture Reynolds Number (Remixture). The region above the solid line 
produced monodispersed liposomes (PDI <0.10) and the region below the solid line formed 
polydispersed liposomes (PDI >0.10). 4b) Flow images corresponding to locations (1, 2, 3, and 
4) from Fig. 4a demonstrating flow profiles leading to monodispersed or polydispersed systems. 
To cover a range of FVR and Remixture, the ethanol containing inner tube diameter (dE) and the 
aqueous containing outer tube diameter (dA) were changed accordingly.  4c) Z-average particle 
size vs. Remixture for only monodispersed liposomes. dA1 = 3.175 mm, dA2 = 4.572 mm, dE1 = 
0.508 mm, dE2=1.016 mm. 
Antonio P. Costa
 
 
 
Fig. 4.5 A Surface profile plot of the Z
(AFR) and lipid concentration. The liposome particle size increases with an increase in the 
injected lipid concentration and/or a decrease in aqueous phase flow rate
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-average particle size vs. the aqueous phase flow rate 
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Fig. 4.6 The effect of lipid type (i.e. DMPC, DPPC, DSPC, DOPC) on mean particle size and 
PDI. The formed liposomes were mostly monodispersed with the majority of PDI values ≤ 0.05. 
Some polydispersity was evident for DOPC liposomes and for liposomes formed at low aqueous 
phase flow rates. The dotted line in the bottom plot represents the limit on monodispersity 
(PDI<0.10). The standard deviation from the Z-Average particle size plot was less than the 
symbols representing the data. 
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Fig. 4.7 The effect of aqueous phase additives on mean particle size. The aqueous phase 
consisted of 10 mM phosphate buffer plus the addition of certain additives (i.e. NaCl, glycerol 
and ethanol). All additives were pre-mixed with the aqueous phase prior to liposome formation. 
The 10 mM Phosphate buffer sample was used as a control. The Z-average particle size 
measured by DLS and PDI are plotted above. 
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Fig. 4.8 Comparison of different particle sizing techniques (dynamic light scattering, 
nanoparticle tracking and particle counting via NS-TEM to assess liposome mean particle size 
and particle size distribution. DLS and nanoparticle tracking are in good agreement with both 
mean size and size distribution. NS-TEM produces a larger particle size and size distribution. For 
all three techniques, the mean particle size trend is the same, i.e. an increase in mean particle size 
for a decrease in the aqueous phase flow rate. Ethanol flow rate = e (mL/min); Aqueous flow rate 
= a (mL/min). 
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Fig. 4.9 Liposome mean particle size and standard deviations for DLS, nanoparticle tracking, 
NS-TEM and Cryo-TEM. The z-average standard deviation was calculated from the PDI (i.e. σ = 
[mean*PDI]1/2 ). The intensity standard deviation was reported directly from the intensity width. 
The nanoparticle tracking standard deviation was reported by the Nanosight® software. The NS-
TEM standard deviation was from the Gaussian distribution fit (R2 ≥ 0.913 for all cases). Error 
bars represent the standard deviation for the multiple data sets. No error bars were reported for 
Cryo-TEM since the particle count was limited. Ethanol flow rate = e (mL/min); Aqueous flow 
rate = a (mL/min). 
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Fig. 4.10 Negative stain TEM micrographs of liposomes for three liposome samples produced 
using different flow conditions. a) 40e:100a sample, b) 40e:150a, c) 40e:375a and d) 40e:375a 
zoomed. Ethanol flow rate = e (mL/min); Aqueous flow rate = a (mL/min). 
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Fig. 4.11 Cryo-TEM micrographs of liposomes for three liposome samples produced using 
different flow conditions. a) 40e:100a sample, b) 40e:150a and c) 40e:375a. Ethanol flow rate = 
e (mL/min); Aqueous flow rate = a (mL/min). 
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Fig. 4.12 Proposed model for liposome formation from a coaxial turbulent jet mixer in co-flow. 
A schematic of a turbulent jet is shown with a radial ethanol concentration gradient (top left). In 
the liposome formation model, lipid and ethanol molecules aggregate (forming pro-liposomes) as 
the ethanol concentration decreases. The pro-liposomes grow in size by “recruiting” lipid 
molecules. The growth continues until the ethanol concentration reduces below a critical level. 
Image not shown to scale. 
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Chapter 5 
 
Continuous Processing of Liposomes with in-line Dilution and at-line Particle Size Analysis 
5.1. Abstract 
In-line dilution was added to a continuous process for forming liposomes. In-line dilution was 
implemented to reduce the overall amount of solvent (ethanol) in the final colloidal dispersion. 
In addition, at-line particle size analysis was also implemented into this process. At-line particle 
size analysis provided enhanced process control of the liposomal dispersions. Two techniques 
were compared, i.e. a continuous flow mode vs. a Load/Stop flow mode. The advantages and 
disadvantages of each technique were outlined with an explanation of limitations. Moreover, the 
effect of forming liposomes at different ionic strengths was investigated. Overall, the Load/Stop 
mode for at-line particle size analysis appeared to provide more consistent dynamic light 
scattering results compared to the Continuous Flow mode. Lastly, the ionic strength of the 
aqueous phase had a significant impact on the mean particle size of the liposomes and a brief 
explanation about the liposome formation mechanism was discussed. 
5.2 Introduction 
In the pharmaceutical industry, liposomes are used as drug delivery systems and have 
demonstrated clinical efficacy in anti-cancer therapies27, 79-82, in an anti-fungal therapy83 and in 
producing postsurgical analgesia84. Two critical quality attributes of liposomal formulations are 
the mean particle size and particle size distribution. The mean particle size diameter range of 
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liposomes is from 25 nm up to >1000 nm. For anti-cancer applications, liposomes with a 
diameter of around 100 nm may be considered optimal with respect to blood-to-tumor transfer 
and increased tumor retention times85. To the contrary, different types of tumors may have lower 
or higher pore cutoff sizes (e.g. 7-2000 nm)86. For the lower pore cutoff, smaller liposomes 
would be required for liposomal extravasation into the tumor. 
 
Moreover, both the mean particle size and particle size distribution have major impacts on 
liposomal in-vitro stability as well as liposomal in-vivo biodistribution and cellular uptake 
mechanisms. For example, liposomes around 40 nm in diameter appear to be internalized by the 
dynamin-dependent pathway and liposomes around 98 nm are internalized by Clathrin-mediated 
endocytosis87. Additionally, it has been documented that small liposomes (~40 nm) are able to 
enter the lymphatic system after subcutaneous administration whereas larger liposomes remained 
at the site of injection.88 With respect to in-vitro stability, large liposomes (micron-sized) may 
have a greater tendency to sediment due to gravity while smaller liposomes are not affected by 
gravitational forces since these particles move via Brownian motion and do not sediment. In 
addition, changes in liposomal particle size and size distribution (i.e. due to fusion or 
aggregation) are affected by the presence of ions, e.g. Ca2+ and La3+.89 Therefore, to ensure 
consistency of in-vitro and in-vivo performance, liposomal formulations should have a defined 
mean particle size and size distribution. 
 
The mean particle size diameter and particle size distribution of liposomes can be analyzed by a 
variety of instruments and technologies. These technologies include but are not limited to: 
dynamic light scattering, static light scattering, particle tracking, various forms of electron 
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microscopy and acoustic spectroscopy. In order to accommodate many liposomal formulations, 
particle sizing technology used to measure liposomes must be capable of measuring particle 
diameters as low as 25 nm. Moreover, many of these technologies are only applicable to off-line 
measurements and cannot be implemented into a process (i.e. batch nor continuous). For a 
continuous process, the measurement must be either at/on/in-line capable. Two technologies that 
have this capability are dynamic light scattering and acoustic spectroscopy.  
 
Dynamic light scattering is based on light or photon fluctuations that are correlated to the 
diffusion of particles, which is then related to particle size information. This technique uses two 
analyses in calculating the particle size data; namely, an intensity-based analysis and an 
intensity-weighted or cumulants analysis. The intensity analysis is based on the raw data (photon 
fluctuations). The cumulants analysis is based on an exponential equation and is weighted 
according to the intensity of the particles. For continuous measurements, this technique can be 
setup in a process stream by the use of a flow cell. The flow cell enables the sample to enter the 
cell at one end and leave the cell at the other. A pump is used to control the flow rate and/or stop 
the flow into the flow cell. If the flow rate is low enough to sustain laminar flow (around 1-1.5 
mL/min), then the sample may constantly flow through the flow cell during measurement. For 
higher flow rates, turbulence develops and the higher velocities impart motion to the particles, 
resulting in erroneous particle size measurements. If higher flow rates are required (>1.5 
mL/min), the sample can be rapidly loaded into the flow cell followed by stopping the flow prior 
to the particle sizing measurement. 
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Acoustic spectroscopy is based on the propagation of sounds waves at multiple frequencies while 
measuring the attenuation of the ultrasound, which is then used in calculating the particle size 
distribution90. There is a correlation between the displacement of the sound waves at multiple 
frequencies with the mean particle size and size distribution85. This technique has successfully 
characterized BCR silica quartz samples with precisions of 1% for particle size and 5% for 
distribution.91 In a second study, microemulsions are measured from 20 nm to 100 nm up to 
16.6% weight fractions.92 These results indicate that relatively concentrated samples can still be 
tested with this technique, which may be problematic for dynamic light scattering. The 
advantage of this technique is that the particle size measurements can be taken at higher flow 
rates that are not constrained to the laminar flow regime as is the case with dynamic light 
scattering. A disadvantage of this technique is that air bubbles will interfere with the particle size 
measurements. 
 
From a quality perspective, it is highly important that the mean particle size and size distribution 
of the liposomal formulation is within specifications. For example, these specifications could be 
that the mean particle size diameter is 100 nm ± 10 nm with a particle size distribution of 25 nm. 
For both batch and continuous processes, the particle size can be measured during or after 
processing. However, continuous processing has the advantage in that the particle size 
measurement can be performed continuously as the liposomes are being formed, and this 
information can be used to: divert out-of-specification liposomes to waste without compromising 
the entire unit or batch; and to correct the problem that caused the formation of out-of-
specification liposomes. In contrast to the continuous process, the particle size measurement for 
a batch process would take place once all of the liposomes are formed and consequently failure 
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to meet the particle size specifications would result in removal of the entire batch.  In this work, 
it is hypothesized that the mean liposome particle size diameter and particle size distribution can 
be quantitatively monitored during continuous processing and this information can be used in a 
feedback algorithm to maintain these liposomal critical quality attributes. 
5.3 Materials and Methods 
5.3.1 Materials 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC); 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC); 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); 1,2-dipalmitoyl-
sn-glycero-3-phospho-(1'-rac-glycerol, sodium salt) (DPPG-Na); and Lipoid S PC-3 (HSPC) 
were purchased from Lipoid™. Cholesterol (Chol) was purchased from Sigma. Ethanol (200 
proof, ACS/USP grade) was purchased from Pharmco-AAPER. 
 
5.3.2 Experimental Methods 
5.3.2.1. Liposome Formation and Dilution 
Liposomes were prepared by a modified ethanol injection method. A schematic of this system is 
demonstrated in Fig. 5.1. Three separate 316 stainless steel tanks contained the lipid+ethanol 
solution. These tanks were pressurized (at 20 psi) and the flow rates from these tanks were 
controlled by analog flow meters (McMillian) and proportioning solenoid valves (Aalborg). The 
flow meters were factory calibrated for water with less than 1% error full-scale. For the 
lipid+ethanol flow streams, these flow sensors were re-calibrated for ethanol and had an R-
squared value of 0.9989, with a working range from 5-50 mL/min. The three tanks were then 
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connected at a single point using a 4-way connector (Swagelok). A static mixer was 
implemented to ensure that the lipid+ethanol solutions from the three tanks were adequately 
mixed prior to reaching the injection port where the ethanol and aqueous phase I streams 
converged. The aqueous phase I volumetric flow rate was controlled by a gear pump 
(Micropump®). To form liposomes, the mixed lipid+ethanol solution was then injected into an 
aqueous phase (aqueous phase I) at various flow rates. The tubing ID of the ethanol phase was 
0.508 mm (1.588 mm OD). The aqueous phase I tubing ID was fixed at 4.572 mm. Flow rates of 
the lipid+ethanol phase ranged from 5-40 mL/min and those of the aqueous phase I ranged from 
70-300 mL/min.  
 
After the liposomes were formed, the liposomes passed through a degassing unit (Liqui-Cel) 
followed by a second three-way T-port. This three-way T-port has one inlet for the liposomes, a 
second inlet for aqueous buffer and one outlet. A second gear pump (Micropump®) was used to 
control the flow of the aqueous phase into this port (aqueous phase II). The aqueous phase II 
flow rate was adjusted such that mixed aqueous phase would always have 5% vol. ethanol. 
Aqueous phase II flow rates ranged from 690-460 mL/min. 
 
5.2.2.2. Data Acquisition System and Computer Software 
The entire process was controlled by a custom-made program written using National Instruments 
(NI) LabVIEW® software. A data acquisition system (NI PXIe-1078) was combined with 
multiple NI modules to accommodate various input/output signals (e.g. analog and digital 
inputs/outputs, counters, circuit switches, etc.).  The entire system was automated and only 
required the user to define the final lipid concentration and molar ratios of lipid. Process 
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variables such as flow rates, pressure, and temperature were monitored and some variables were 
automatically adjusted using custom computer algorithms. For example, proportional-integral-
derivative controls were implemented in the computer program to precisely control the flow rates 
of both the ethanol and aqueous phases. 
 
Communication to and from the Malvern Zetasizer was accomplished using the Malvern Link II 
software. Malvern Link II software was setup as an OPC server and NI LabVIEW was setup as 
an OPC client. The z-average particle size and PDI were recorded in the custom computer 
program. The custom computer program was able to send measurement instructions to the 
Malvern Zetasizer. 
 
5.2.2.3. Experimental Outline for Liposomal Dilution 
The impact of diluting liposomes was tested for liposome formulations consisting of 
lipid:DPPG:Chol at a molar ratio of 4.5:0.4:3, where lipid was either DPPC or DMPC. These 
lipids were chosen since each lipid was previously investigated and they produced liposomes of 
different sizes, i.e. up to ~500 nm for DMPC vs. up to 150 nm for DPPC. Two processing setups 
were investigated for the in-line dilution of liposomes. The first processing setup (setup I) was 
injecting the formed liposomes directly into the aqueous phase II (without the contactor in Fig 
5.1). The second processing setup (setup II) consisted of incorporating a contactor (degassing 
unit) at the end of the liposome formation stage prior to the ethanol dilution stage (Fig. 5.1). For 
each processing setup, aqueous phase I flow rates ranging from 70 mL/min to 300 mL/min were 
tested. The aqueous phase used in this experiment was 10 mM phosphate buffer at pH = 7.4. 
Each sample was analyzed for mean particle size and polydispersity index (see section 5.2.2.5). 
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5.2.2.4. Temperature Effects on Liposome Formation and Dilution 
For the sample liposomal formulations outlined in section 5.2.2.3, these formulations were tested 
using the second processing setup over a range of temperatures. A chiller was connected to a 
custom designed heat sink and the aqueous phase I was chilled in-line to a set temperature (e.g. 
8°C). The flow rate of the aqueous phase I was fixed at 100 mL/min. The temperature at the 
liposome formation stage was recorded in addition to the temperature of the aqueous phase II. 
Each sample was analyzed for mean particle size and polydispersity index (see section 5.2.2.5). 
 
5.2.2.5. Particle Size Measurements 
All particle size measurements were performed with a Malvern Zetasizer Nano S. Both off-line 
and at-line measurements were completed. Prior to measurements, the liposomes were diluted in-
line to 5% vol. ethanol and the viscosity and refractive index were pre-set in the Malvern 
Zetasizer software. Particle size measurements included the z-average particle size and 
polydispersity index (PDI). For the off-line measurements, disposable plastic cuvettes were used. 
The samples were equilibrated at 25°C prior to each measurement. Each off-line measurement 
duration was set for 10 runs at 10 seconds each with n=3. 
 
For at-line measurements, a flow cell equilibrated at 25°C was used. Prior to running at-line 
measurements, a population of liposomes with a low PDI was analyzed for various measurement 
conditions (i.e. attenuation, run duration, and count rate). Based on these results, the run duration 
was fixed (between 6-8 seconds) and the attenuation (and count rate) were adjusted to a 
satisfactory signal for DLS analysis. Two approaches were taken to transfer sample to the 
Malvern Zetasizer. The first approach (Continuous Flow Mode) was when the liposomes flowed 
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at a constant flow rate 1-1.5 mL/min through the flow cell while the particle size measurement 
was taken. The setup for this approach consisted of a miniature solenoid pump (Biochem™) that 
pumped the sample from the process stream to the Malvern Zetasizer. This pump operates by 
pumping 70 uL for each actuation and by controlling the actuation frequency, precise flow rates 
can be maintained.  
 
The second approach (Load/Stop Mode) was based on loading the flow cell followed by stopping 
the flow prior to the measurement. A Micropump® pump was used to control the flow through 
the flow cell (20-25 mL/min). The pump operated at the set flow rate just prior to particle size 
measurements, at which point a custom computer algorithm then stopped the pump to prevent 
fluid flow during the measurements. 
 
5.2.2.6. Automatic Particle Size Control 
A liposome formulation consisting of HSPC:Chol:DPPG (4.5:3:0.4 molar ratio) was used to 
form the liposomes. The particle size was automatically controlled via the custom LabVIEW 
program. Initially, a model was established as a feedforward control using information such as 
salt concentration and type of lipid to reach a user defined particle size. This feedforward control 
provided an estimate of the aqueous phase I flow rate (ml/min) required to form liposomes of the 
user defined particle size.  To maintain the particle size, a feedback algorithm was implemented 
using a proportional-integral-derivative (PID) control with the at-line particle size analysis via 
the Malvern Zetasizer as the process control input.  
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5.3 Results 
5.3.1. Effect of Contactor prior to Ethanol Dilution 
After the liposomes were formed, the liposomal dispersion was diluted to reach 5% vol. ethanol. 
The liposomes were diluted using the following two processing setups outline in the methods, 
namely: (1) setup I: without the contactor and (2) setup II: with the contactor. For DPPC 
liposomes, the addition of a contactor did not cause any major changes in the mean particle size 
nor the PDI value over the entire flow rate range. For DMPC liposomes, the contactor only 
appeared to cause changes at the lower aqueous phase I flow rate (i.e. 70 mL/min). At 70 
mL/min, the mean particle size was larger and the PDI was lower compared to DMPC liposomes 
without the contactor. These results indicate that a larger dynamic range of particles that are 
more monodispersed are only obtained when the contactor is positioned at the end of the 
liposome formation stage. 
 
5.3.2. Temperature Effects on Liposome Formation and Dilution 
For these experiments, the temperature of the aqueous phase I and aqueous phase II were the 
same. When the ethanol+lipid phase was injected into the aqueous phase I, exothermic mixing 
caused an increase in temperature. The mean particle size and PDI for the DPPC liposomes 
exhibited an inverse relationship with an increase in temperature at the liposome formation stage 
(Fig. 5.3). This observation implies that at higher temperatures, larger liposomes form; however, 
at higher temperatures, the PDI also tends to increase. For DPPC liposomes, the PDI value did 
not exceed 0.1 even at the highest temperature, indicating that all of the liposomes, regardless of 
the temperature at liposome formation, were monodispersed. 
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Sizing data for DMPC liposomes also demonstrated an inverse relationship with an increase in 
temperature at the liposome formation stage (Fig. 5.4); however, significant changes in both the 
PDI and mean particle size occurred around 25°C. As the temperature increased from 24°C, the 
PDI increased from less than 0.09 ± 0.02 up to 0.24 ± 0.02. This change in PDI indicates that the 
particle size distribution was wider and/or multiple populations of liposomes were present as the 
temperature increased. In addition, the mean particle size of the liposomes increased significantly 
from 26°C up to 29°C, i.e. from 171.1 ± 1.7 nm to 333.5 ± 4.03 nm. 
 
5.3.3. DLS Measurement Analysis 
A previously prepared sample of liposomes was placed in the DLS flow cell and the DLS 
attenuation and cell position settings were set to automatic. These settings resulted in an 
optimized attenuation setting of 9 and a cell position of 4.2 – with the run duration fixed at 3 runs 
for 10 seconds each. The particle size information resulted in a z-average of 56.50 ± 0.03 nm, a 
PDI of 0.05 ± 0.02 and a count rate of 401.4 ± 2.77. Manual measurements were then taken at 
different attenuations (6, 7, 9 and 11) and run durations (3, 9, or 15 seconds) for a single run 
only. The plots from Fig 5.5a-c indicate how changing the DLS measurement settings impact the 
particle size analysis. From figure 5.5a, the z-average for this sample was most accurate at an 
attenuation of 7-9. At a higher value (i.e. 11), the particle size decreased. The PDI was similar to 
the control sample at the high attenuation (Fig. 5.5b). At a low attenuation (i.e. 6), the particle 
size was incorrect due to a very low count rate (Fig. 5.5c). In addition, the PDI increased 
significantly for this measurement. From these results, it is apparent that the count rate should be 
around or greater than 40 kcps and less than 500-1000 kcps for accurate particle size analysis. 
Lastly, the run duration did not appear to cause significant changes to the particle size analysis. 
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However, a higher value would increase the number of photons collected and would provide a 
more accurate particle size analysis. 
 
5.3.4. At-line Particle Size Analysis - Approach 1: Continuous Flow Mode 
The at-line particle size analysis via the continuous-flow mode was accomplished using a micro-
solenoid pump that pumped the liposome samples at a constant flow rate (referred to as DLS 
flow rate) through the DLS flow cell during the particle size measurement. An initial study was 
conducted to determine DLS flow rates that resulted in similar particle size data to that obtained 
using off-line measurements. Liposomes composed of DPPC:Chol:DPPG (4.5:3:0.4 molar ratio) 
were formed at three aqueous phase flow rates (i.e. 80, 100 and 150 mL/min). The at-line particle 
size measurements were compared with the off-line particle size measurements. From Fig 5.6, 
the mean particle size was similar for both the continuous flow mode and the off-line 
measurements at the three different aqueous phase I flow rates and for DLS flow rates at ~ 1 and 
2 mL/min. To the contrary, the PDI was only similar when the DLS flow rate was around 1 
mL/min. At 2 mL/min in the continuous flow mode, the standard deviations and mean PDI were 
larger when compared to the off-line measurements. Therefore, the subsequent experiments for 
the continuous flow mode operated with a DLS flow rate around 1 mL/min. 
 
Liposomes were then analyzed over a period of time to investigate how process changes (i.e. 
flow rate changes) impacted the mean particle size and PDI with respect to both accuracy and 
measurement lag time. Measurement lag time is the difference in time between a process change 
to the corresponding particle size data that is recorded in the custom software. This lag time is 
from the DLS measurement (e.g. run duration and temperature equilibration), delays in 
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software/instrument communication and time required to remove the previous sample in the DLS 
flow cell. The liposomal samples from Fig. 5.7 were run at 1 mL/min and showed agreement 
between some of the continuous particle size data and the off-line data. The mean particle sizes 
and PDI values for both continuous and off-line measurements were similar except for after the 
flow rate change. These anomalies may be explained by air bubbles entering the flow cell. In 
addition, there was a 58 second delay between the process changes to when the corresponding 
particle size data was recorded in the custom LabVIEW program. 
 
A second analysis was conducted using for DPPC:Chol:DPPG (4.5:3:0.4 molar ratio) liposomes 
in 10 mM Hepes buffer (Fig 5.8). For this experiment, the liposomes flowed through a degassing 
unit prior to entering the DLS flow cell. The off-line particle size measurement data at the 100 
mL/min aqueous 1 phase overlapped the continuous measurement data. At 150 mL/min, the 
particles became smaller (i.e. approximately 45 nm) and the particle measurement data for the 
off-line and continuous measurements did not correspond. The mean particle size was different 
by 15 nm and the continuous mode PDI ranged from 0.20 – 0.33, but was 0.05 for the off-line 
measurement. In addition, the measurement lag time was from 109 – 137 seconds. 
 
5.3.5. Approach 2: Load/Stop Mode 
For this approach, the liposomes were loaded into the flow cell at 20-25 mL/min prior to the 
DLS measurement. At 1-2 seconds before the DLS measurement, the flow was stopped. After 
the DLS measurement was completed, the flow began again and this process repeated for the 
duration of the experiments. The experiments here were designed to accommodate small and 
large liposomes using the same lipid formulation, i.e. DPPC:Chol:DPPG (4.5:3:0.4 molar ratio). 
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To achieve different sizes, three different aqueous phases were investigated, i.e. 10 mM NaCl, 75 
mM NaCl and 140 mM NaCl. Liposomes prepared in 10 mM NaCl formed liposomes ranging 
from approximately 70 nm down to 45 nm in diameter (Fig 5.9).  Slight deviations for the 
continuous particle size and off-line particle size were observed. The PDI was similar and less 
than 0.2 in all cases. The measurement lag time appeared to be consistent around 40-47 seconds. 
Process temperatures at both liposome formation and at the ethanol dilution stage were recorded 
as both of these temperatures have an impact on the mean particle size and PDI. 
 
Liposomes prepared in 75 mM NaCl formed liposomes ranging from approximately 145 nm 
down to 70 nm in diameter (Fig 5.10).  The mean particle size for the continuous and the off-line 
measurements overlapped for the majority of each flow condition. The same observation was 
true for the PDI values. The measurement lag time appeared to vary from 4-39 seconds; 
however, the 4 second may have been an anomaly. More accurately, the lag time appears to be 
constant around 29-39 seconds. 
 
Liposomes prepared in 140 mM NaCl formed liposomes ranging from approximately 160 nm 
down to 70 nm in diameter (Fig 5.11).  The mean particle size for the continuous and the off-line 
measurements also overlapped for the majority of each flow condition. The same observation 
was true for the PDI values. The measurement lag time was from 28-42 seconds, consistent with 
the previous two salt conditions.  
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5.3.5. Ionic Strength on Liposomal Physical Properties 
The off-line particle size data from Fig. 5.9 to 5.11 were replotted vs. flow rate (Fig 5.12). It is 
clear that the mean particle size has a dependence on the amount of NaCl present in the aqueous 
phase. At low salt concentrations, i.e. 10 mM NaCl and 10 mM PB, pH 7.4, the particles were 
smaller compared to higher salt concentrations. There was not a large difference between the 
liposomes prepared in 75 mM NaCl and 140 mM NaCl. Thus, the NaCl concentration appears to 
have more of an impact on the particle size in between 10 to 75 mM NaCl. The 10 mM 
phosphate buffer had an ionic strength of 0.025 M, and the liposomes that formed under this 
condition had a mean particle size that was in between the 10 mM NaCl and 75 mM NaCl. 
 
The zeta-potential was measured for the liposomes prepared in 10-140 mM NaCl and for 10 mM 
phosphate buffer (Fig 5.13). As the NaCl concentration increases, the zeta-potential on the 
particles decreases. This decrease in zeta-potential corresponds to a decrease in the particle size 
for the liposomes prepared in NaCl. Liposomes prepared in 10 mM phosphate buffer had a 
similar zeta-potential to those prepared in 10 mM NaCl; however, the particle size of the 10 mM 
phosphate buffer liposomes were more similar to liposomes prepared in 75 mM NaCl. 
 
5.3.6. Automatic Particle Size Control 
The feedforward model used related the flow rate to the particle size, type of lipid and salt 
concentration. The feedback control used a PID controller with the following settings: P = 1.5, I 
= 0.3 and D = 0.001. Two particle size set points were set during this experiment, i.e. 60 nm and 
80 nm. Once the set point particle size was reached, the user adjusted the particle size set point to 
the other set point (Fig. 5.14). Initially, the feedforward algorithm was able to accurately predict 
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the particle size. After this initial prediction, the feedback algorithm took over to maintain the 
particle size at the set point. From Fig. 5.14, it was clearly demonstrated that the feedback 
control satisfactory maintained the mean particle size and was able to automatically adjust the 
flow rates to achieve the set point particle size (i.e. from 60nm to 80nm or vice versa). The PDI 
remained around 0.1 or less during the entire experiment. The DLS count rate fluctuated based 
on the flow rate conditions, but was within a range that was previously determined to provide 
satisfactory particle size analysis. 
5.4. Discussion 
5.4.1. In-line Liposomal Dilution 
The first part of this work outlined the importance of degassing the liposomes at the end of the 
liposome formation stage prior to the ethanol dilution stage. As mentioned, the mixing of ethanol 
with an aqueous phase is exothermic and leads to sensible heat changes. These heat changes 
caused dissolved gas to leave the solution, forming bubbles/ an air-water interface. For DPPC 
liposomes, the presence of bubbles did not appear to affect the liposomal particle size 
distributions. For DMPC liposomes, the particle size distribution was affected at the lower 
aqueous phase I flow rates, but not at the higher flow rates. Moreover, it was observed that at the 
lower aqueous phase I flow rates (i.e. 70 mL/min), foam was visible for the DMPC liposomes, 
but not for the DPPC liposomes. This foaming may be due to a reduction in surface tension as 
temperature increased – subsequently causing an increase in the mobility of the lipid molecules. 
This analysis was further corroborated by Fig. 5.3 and Fig 5.4. In these figures, a change in 
temperature caused changes in liposomal mean particle size; although, to a greater extent for 
DMPC liposomes than for DPPC liposomes. In addition, DMPC liposomes exhibited an 
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increased particle size distribution (higher PDI) as temperatures exceeded 24°C and a significant 
change in mean particle size as temperatures exceeded 26°C. These events can be explained 
since the transition temperature for the DMPC phospholipid is around 24°C, which would cause 
this lipid to experience a more fluid-like behavior near and/or above this temperature.2 This 
increased lipid mobility resulted in the formation of larger liposomes, as well as increased 
foaming. For the DPPC phospholipid, the phase transition temperature is closer to 41°C,2 which 
explained why DPPC liposomes did not exhibit larger particle size changes compared to DMPC 
liposomes over the temperatures investigated. 
 
When foam formed at the liposome formation stage and passed into the ethanol dilution stage 
(aqueous phase II), this dilution stage became a second stage of mixing, which caused the foam 
to mix back into the aqueous phase and formed a second population of liposomes. The liposomes 
formed at the dilution stage would then depend on the mixing at the dilution stage, i.e. the 
Reynolds number and temperature. Since the flow rates ranged from 460-660 mL/min, the 
Reynolds number at this stage would be >1000 and supported the formation of smaller 
liposomes. Therefore, with the addition of foam, a larger particle size distribution existed 
because essentially two populations of particles formed, one at the liposome formation stage and 
one at the ethanol dilution stage. By removing the foam after liposome formation, the tendency 
to form a second population of particles was reduced.  
 
As previously explained, the Reynolds number may be used as a predictive measure of particle 
size; however, it is only suitable with fixed conditions such as lipid concentration, types of salts, 
salt concentrations, etc. A lower Reynolds number supports larger liposomes while a higher 
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Reynolds number supports smaller liposomes37. By lowering the temperature at the liposome 
formation stage, this would cause the Reynolds number to decrease, and the liposome particle 
size to decreases. Therefore, the Reynolds number alone is not a satisfactory measure for the 
liposome formation process. Instead, a more a thorough model should be established that takes 
into account factors such as the Reynolds number, temperature, lipid-phase transition 
temperature, lipid hydrocarbon saturation and buffer/salt composition.  
 
5.4.2. Variables that Influence Particle Size Measurements 
There are many important variables that influence accurate particle size measurement of 
liposomes for at-line measurements. These variables can be divided into processing variables and 
DLS measurement variables (Table 5.1). For processing variables, the first is the total dead 
volume, i.e. the volume of the tubing from the process stream to the flow cell plus the volume of 
the flow cell. This volume is important since this is the volume that must be replaced after each 
measurement; otherwise, liposomes that were formed at earlier time points will be mixed with 
liposomes formed at later time points. Large total dead volumes will incur a large time shift with 
respect to processing conditions.  
 
A second processing variable is the process stream to flow cell velocity ratio. This ratio is the 
velocity of the liquid in the process stream divided by the velocity of the liquid flowing to the 
flow cell. In order to achieve a small time shift, this value must >>1. This variable is linked with 
the total dead volume since higher ratios cannot be achieved with large dead volumes, especially 
at flow rates around 1-1.5 mL/min. For example, the DLS flow cell volume used in these 
experiments is 100 µL and the total volume including the pump and tubing was approximately 
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220 µL. Moreover, if DLS measurements were taken every 15 seconds, then 250 µL of sample 
would pass through during this time. Ideally, since the flow cell has a larger volume than the 
tubing, it may require more volume to remove the entire previous sample (i.e. 2-3x the total dead 
volume) and longer delay times in between measurements would be required.  
 
A third processing variable is whether laminar flow occurs. This variable is only important for 
the constant flow mode. For this variable, small inner diameter tubing (e.g. 0.01”) may cause 
turbulence and affect the Brownian motion of the particles, thus resulting in incorrect particle 
size measurements. To reduce these effects, larger inner diameter tubing should be used; 
however, larger inner diameter tubing will increase the total dead volume. 
 
DLS measurement variables include settings such as measurement duration, number of runs and 
attenuation factor. The measurement duration for each DLS run can be set in the Zetasizer 
software. For off-line DLS measurements, each measurement consisted of approximately 10-15 
runs and each run lasted 10 seconds. The DLS data from each run was then combined to provide 
a single DLS result. Additionally, the mean count rate measured in kilo counts per second (kcps) 
should be greater than 20 kcps and less than 1000 kcps.93 For lower photon counts, the data may 
not result in an accurate particle size analysis. For the at-line measurements, only a single run of 
6 second duration was used for the DLS measurements, which would result in a low photon 
count. However, from Fig. 5.7 – Fig 5.11, the 6 second duration was adequate for determining 
the z-average particle size and in most cases, the PDI was similar for both off-line and at-line 
measurements. Shorter measurement durations (e.g. 3 seconds) may have also provided 
satisfactory results, but would lead to a lower photon count. Therefore, the at-line measurement 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
93 
 
experiments used a longer measurement duration (i.e. 6 seconds) to achieve more consistent and 
higher quality data.  
 
The attenuation factor is another important variable. A low attenuation factor refers to when a 
lesser amount of light passes through the sample and a high attenuation factor is when a greater 
amount of light passes through the sample (for a Malvern Zetasizer, the attenuation range is from 
0-11, respectively). Changing the attenuation factor will cause the photon count rate to increase 
or decrease; however, very high count rates will no longer provide accurate data since the DLS 
detector has a maximum count rate where the response remains linear. For the off-line 
measurements, the count rate was set to “automatic” in the Zetasizer software. For the at-line 
measurements, the count rate was kept between 150-400 kcps by programmatically adjusting the 
attenuation factor depending on the particle size of the liposomes being tested. The advantage of 
a user-defined attenuation is the reduced overall time per measurement. The disadvantage is that 
the user-define attenuation factor may not allow for a sufficiently high photon count during 
measurement – resulting in lower quality data. 
 
A fourth measurement variable is the presence of air bubbles in the sample. Air bubbles will 
affect the overall quality of the results since the air bubbles also scatter light. One way to 
circumvent this issue is to use a degassing unit between where the sample is taken and the DLS 
flow cell. The disadvantage of using a degassing unit is that the volume of the degassing unit 
adds to the total dead volume, resulting in longer measurement delays (Fig. 5.7). 
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5.4.3. At-line Particle Size Measurements Comparisons 
By comparing the Continuous Flow mode vs. the Load/Stop Mode, the Load/Stop mode 
appeared to be more accurate and had a more consistent measurement time-delay. When using 
the Load/Stop mode, the entire sample was removed from the DLS flow cell since the flow rates 
were around 20-25 mL/min vs. 1-1.5 mL/min for the Continuous Flow mode. In addition, a 
larger inner diameter tubing was used for the Load/Stop mode and this may have reduced air 
bubble formation, resulting in fewer artifacts present with the DLS data. One disadvantage of the 
Load/Stop approach is the rapid loading of the flow cell, which does not allow for temperature 
equilibration. In this case, the sample temperature may be different than the temperature set in 
the DLS software, which could explain why the mean particle size, especially for smaller 
liposomes, was lower when compared to the off-line DLS measurement (Fig. 5.8). This deviation 
was only observed for small liposomes (i.e. <50 nm).  
 
5.4.4. Ionic Strength on Liposome Formation 
The ionic strength of the aqueous phase significantly affected the liposome mean particle size. 
From Fig. 5.12, 10 mM NaCl formed 70 nm liposomes and 140 mM NaCl formed around 160 
nm liposomes at the same flow rate (i.e. 70 mL/min). The portion of the phospholipid molecule 
that is in contact with the aqueous phase is the phosphate head group. Accordingly, the head 
group may be changing in size (e.g. mean molecular area) and would influence lipid packing. 
Moreover, by comparing liposomes prepared in 10mM NaCl to 10 mM phosphate buffer (at pH 
7.4), the liposomes prepared in 10 mM NaCl were smaller in diameter. When taking into account 
the ionic strength, the 10 mM phosphate buffer had an ionic strength greater than 10 mM NaCl 
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but less than 75 mM NaCl. Therefore, an increase in ionic strength caused an increase in 
liposomal mean particle size.  
 
The ionic strength affects the electrostatic or charge repulsion of neighboring phospholipid 
molecules (Fig 5.12). At a low ionic strength (e.g. 10 mM NaCl), the repulsion would be greater 
than at 140 mM NaCl since a high salt concentration would lower the overall zeta-potential of 
the particles (Fig 5.13). This is explained by the Gouy-Chapman-Stern theory, which describes 
how increasing the salt concentration decreases the distance from the charged surface to the 
plane of shear94. When large amounts of charged species (e.g. Na+) associate with negatively 
charged phospholipid membranes, the magnitude of the zeta-potential is reduced95. In addition, 
the amount of cholesterol in the lipid bilayer affects the binding of Na+ to phospholipids and 
causes a reduction in the surface charge96.  Moreover, different salt species (e.g. NaCl vs NaSO4) 
will affect the overall surface charge density based on the lyotropic series97, i.e. strongly 
hydrated anions cause a reduction in the surface charge density. According to a previously 
described liposome formation model, a lower zeta-potential (or surface charge density) may 
allow for more phospholipids to enter the pro-liposomes and hence result in the formation of 
larger liposomes.37  
 
A second explanation for the increase in size with increase in NaCl concentration is related to 
local heat effects as the liposomes are initially forming. The excess enthalpy of mixing for the 
ternary mixture of ethanol, water and NaCl becomes more positive as the salt concentration 
increases98. Reduced enthalpy of mixing indicates more bond breaking events are occurring 
compared to low salt conditions, i.e. less water-ethanol hydrogen bond formation. This event 
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may suggest that more ethanol is interacting with the lipid molecules during the initial mixing 
stage, thus promoting larger lipid aggregates to form prior to liposomes formation. However, 
either explanation, i.e. electrostatic or changes in enthalpy of mixing would be difficult to 
measure directly since liposome formation is taking place at the molecular level and under 
turbulent flow conditions. A future study on changing the phospholipid molar ratio of the 
charged phospholipid may be a suitable alternative to exploring the effects of charge repulsion 
on the liposome formation process. 
 
5.4.5. Automatic Particle Size Control 
In the continuous manufacturing of liposomes, process changes such as pressure or temperature 
fluctuations will cause changes in the liposomal particle size during the liposome formation 
process. Using feedforward control to initially predict the process conditions (i.e. aqueous phase 
I flow rate) and a feedback control to maintain the particle size was demonstrated. By 
implementing these control strategies, liposomal critical quality attributes (i.e. mean particle size 
and particle size distribution) could be maintained, which supported an overall higher quality 
formulation. 
5.5. Conclusions 
In-line dilution of liposomes to reduce the ethanol concentration was implemented in this 
continuous process to form liposomes. Incorporating the in-line dilution stage post the liposome 
formation process may cause changes to the liposomal particle size distribution – depending on 
the liposomal formulation. Therefore, it was determined to be necessary to include a degassing 
unit post liposome formation and prior to the in-line dilution stage. At-line particle size analysis 
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was implemented into the continuous processing of liposomes. To reduce time delays between 
process changes (i.e. flow rates) and the particle size measurement data, it was determined that 
the Load/Stop mode provided more consistent results when compared with the Continuous flow 
mode. In addition, the ionic strength of the aqueous phase significantly impacted the mean 
particle size of the liposomes, i.e. an increase in ionic strength favored the formation of larger 
liposomes. Lastly, automatic particle size analysis was implemented using both a feedforward 
and a feedback control, which resulted in precise control and maintenance of the liposomal 
particle size and polydispersity index. 
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5.6. Tables 
 
Table 5.1. Variables that Influence Continuous Particle Size Measurements 
Processing Variable DLS Measurement Variables 
Total Dead Volume Measurement Duration 
Process Stream to Flow Cell Velocity Ratio  Attenuation Factor 
Laminar Flow Ratesa Sample Temperature 
 Air Bubble Presence 
a = applicable only for constant flow approach 
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5.7. Figures 
 
 
Fig. 5.1 Schematic representation of the liposome formation stage followed by the ethanol 
dilution stage. Two temperature readings via thermocouples are taken at each stage and a 
contactor (degassing unit) is positioned in some cases at the end of the liposome formation stage. 
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Fig 5.2 Liposome mean particle size and polydispersity index for both lipid:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes, where lipid refers to either DMPC or DPPC. Both z-average 
particle size (top) and polydispersity index (PDI, bottom) are plotted vs. aqueous phase I flow 
rate (mL/min). 
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Fig 5.3 Liposome mean particle size and polydispersity index for DPPC:Chol:DPPG (4.5:3:0.4 
molar ratio) liposomes. The mean particle size and PDI is plotted against the temperature (°C) at 
the liposome formation site (see Fig 5.1). The aqueous phase I flow rate was kept constant at 80 
mL/min. 
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Fig 5.4 Liposome mean particle size and polydispersity index for DMPC:Chol:DPPG (4.5:3:0.4 
molar ratio) liposomes. The mean particle size and PDI is plotted against the temperature (°C) at 
the liposome formation site (see Fig 5.1). The aqueous phase I flow rate was kept constant at 70 
mL/min. 
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Fig 5.5 A comparison of manual DLS measurement settings on the liposome particle size (z-
average), the PDI and the DLS count rate (kcps). All results were from a single run at either 3, 9 
or 15 seconds. The liposome formulation was the same for all measurements and had a z-average 
of 56.50 ± 0.03 nm, a PDI of 0.05 ± 0.02 and a count rate of 401.4 ± 2.77. 
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Fig 5.6 Liposome mean particle size and polydispersity index for DPPC:Chol:DPPG (4.5:3:0.4 
molar ratio) liposomes.  The mean particle size and PDI is plotted against aqueous phase I flow 
rate. The flow rates in the bottom plot in red are the DLS flow rates or the flow rate of the 
sample during the DLS measurement.  
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Fig 5.7 Liposome mean particle size and polydispersity index (PDI) for DMPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 10 mM Phosphate Buffer.  The mean particle size, PDI and 
aqueous phase I flow rate is plotted over a period of time. The DLS flow rate was fixed at 1 
mL/min. The aqueous phase was initially at 15°C prior to liposome formation. 
 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
106 
 
 
Fig 5.8 Liposome mean particle size and polydispersity index (PDI) for DPPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 10 mM Hepes buffer.  The mean particle size, PDI and 
aqueous phase I flow rate is plotted over a period of time. The DLS flow rate was fixed at 1 
mL/min. 
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Fig 5.9 Liposome mean particle size and polydispersity index  (PDI) for DPPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 10 mM NaCl.  The mean particle size, PDI and aqueous 
phase I (AFR I) flow rate is plotted over a period of time. 
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Fig 5.10 Liposome mean particle size and polydispersity index (PDI) for DPPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 75 mM NaCl.  The mean particle size, PDI and aqueous 
phase I (AFR I) flow rate is plotted over a period of time. 
 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
109 
 
 
Fig 5.11 Liposome mean particle size and polydispersity index (PDI) for DPPC:Chol:DPPG 
(4.5:3:0.4 molar ratio) liposomes in 140 mM NaCl.  The mean particle size, PDI and aqueous 
phase I (AFR I) flow rate is plotted over a period of time. 
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Fig 5.12 Liposome mean particle size (z-average, d.nm) for DPPC:Chol:DPPG (4.5:3:0.4 molar 
ratio) liposomes in 10-140 mM NaCl (green, red, blue) and 10 mM PB (orange).  The mean 
particle size is plotted against the aqueous phase I flow rate and the ionic strength. 
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Fig 5.13 Liposome zeta potential for DPPC:Chol:DPPG (4.5:3:0.4 molar ratio) liposomes in 10-
140 mM NaCl and 10 mM phosphate buffer (PB).  The zeta potential is plotted against the 
aqueous phase I flow rate.  
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Fig 5.14 An example of automatic particle size control for HSPC:Chol:DPPG (4.5:3:0.4 molar 
ratio) liposomes prepared in 10 mM NaCl is shown.  The mean particle size, polydispersity index 
(PDI), count rate (kcps) and aqueous phase I flow rate (mL/min) is plotted against time (s). The 
arrows indicate when the user changed the particle size set point in the software. 
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Chapter 6 
 
Continuous Processing of Liposomes with In-line Concentrating 
6.1 Abstract 
Continuous processing is an approach that supports and ultimately leads to higher quality drug 
products. In the current work, a concentrating system was integrated with a previously designed 
continuous process for forming liposomes. The combination of both systems leads to improved 
control over the final liposomal formulation. Liposomes were prepared by a modified ethanol 
injection method. A dual channel turbidity sensor using two simultaneous channels, i.e. light 
absorption and light scattering; combined with a tangential flow filtration device, a pump and a 
custom developed computer program was used to control the concentration. In addition, an 
empirical equation was developed using the quality design approach to predict the final lipid 
concentration.   
6.2. Introduction 
Continuous processing is an approach that supports and ultimately leads to higher quality drug 
products. A major challenge in developing a continuous process is process control. Process 
control may include simple measurements such as temperature, pressure and volumetric flow 
rates and more advanced measurements such as particle size, particle size distribution and the 
concentration of excipients/active pharmaceutical ingredients. In order to continuously control a 
specific process in real-time, process analytical technology (PAT) under closed loop control 
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should be implemented. In addition, using tools related to the quality be design approach will 
enhance the overall process control. In the current work, a concentrating system was integrated 
with a previously designed continuous process for forming liposomes37 (Chapter 4 and Chapter 
5). The combination of both systems leads to improved control over the final liposomal 
formulation. 
 
The total lipid concentration is a critical quality attribute for liposomal drug products. The total 
lipid concentration may refer to the amount of phospholipid and/or other lipid molecules such as 
cholesterol that form the liposomal bilayer. The lipid concentration can be used to estimate the 
amount of liposomal vesicles, which may further be related to either drug encapsulation25, i.e. 
drug molecules in the aqueous compartment of the liposomes, to drug loading99 or to the 
intercalation of molecules within the lipid bilayer100. In addition, lipid concentration is used to 
effectively evaluate drug-to-lipid ratios. For example, doxorubicin-to-lipid ratios of 0.3:1 led to 
an increase in biological activity in mice29. 
 
Liposomal lipid concentrations may be toxic depending on the type of lipid in the liposome 
composition. For example, phosphatidylglycerol and phosphatidylserine liposomes were toxic 
from 0.13-3.0 mM for some cultured human cell lines whereas dipalmitoylphosphatidylcholine 
containing liposomes were non-toxic at 4 mM.101 In addition, certain lipid concentrations may 
promote cytotoxicity and can be used as a measure to determine drug effects on changes in IC50 –
values. For example, amphotericin B containing liposomes increased the IC50-value in a 
macrophage-like cell line (Raw 264.7) when compared to liposomes without amphotericin B.102 
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Moreover, macrophage cells are major sites of liposomal accumulation103 and high lipid 
concentrations may cause macrophage cells to exhibit phospholipid overload and inhibit 
phagocytic function104-105. 
 
FDA-approved drug products are formulated with total lipid concentrations ranging from 9.15 
mg/mL up to 103 mg/mL, with the majority in the range from 9.15 mg/mL – 34.88 mg/mL.27, 79-
84
 This provides a pharmaceutically relevant range of lipid concentrations that are considered 
safe and effective. It should be noted that the lipid concentration alone is not sufficient in 
determining safety, as the individual lipid components may be cytotoxic, especially cationic 
lipids106. In the current study, the concentrating system should at least be capable of 
concentrating the liposomes to achieve a lipid concentration within the stated range – making the 
system pharmaceutically feasible.  
6.2. Materials and Methods 
6.2.1. Materials 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phospho-
(1'-rac-glycerol) (sodium salt) (DPPG-Na) and Lipoid S PC-3 (HSPC) were purchased from 
Lipoid™. Cholesterol (Chol) was purchased from Sigma. Ethanol (200 proof, ACS/USP grade) 
was purchased from Pharmco-AAPER. 
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6.2.2. Experimental Methods 
6.2.2.1. Liposome Formation and Dilution 
Liposomes were prepared by a modified ethanol injection method. A schematic of this system is 
depicted in Chapter 5, Fig. 5.1. Three separate 316 stainless steel tanks contained the 
lipid+ethanol solution. These tanks were pressurized (at 20 psi) and the flow rates from these 
tanks were controlled using analog flow meters (McMillian) and proportioning solenoid valves 
(Aalborg). The flow meters were factory calibrated for water with less than 1% error full-scale. 
For the lipid+ethanol flow streams, these flow sensors were re-calibrated for ethanol and had an 
R-squared value of 0.9989, with a working range from 5-50 mL/min. The three tanks were then 
connected at a single point using a 4-way connector (Swagelok). A static mixer was 
implemented to ensure that the lipid+ethanol solutions from the three tanks were adequately 
mixed prior to reaching the injection port where the ethanol and aqueous phase 1 streams 
converged. The aqueous phase I volumetric flow rate was controlled by a gear pump 
(Micropump®). To form liposomes, the mixed lipid+ethanol solution was then injected into an 
aqueous phase (aqueous phase I) at various flow rates. The tubing ID of the ethanol phase was 
0.508 mm (1.588 mm OD). The aqueous phase I tubing ID was fixed at 4.572 mm. Flow rates of 
the lipid+ethanol phase were from 5-40 mL/min and aqueous phase I were from 70-300 mL/min.  
After the liposomes were formed, the liposomes passed through a degassing unit (Liqui-Cel®) 
followed by a second three-way T-port. This three-way T-port has one inlet for the liposomes, a 
second inlet for aqueous buffer and one outlet. A second gear pump (Micropump®) was used to 
control the flow of the aqueous phase into this port (aqueous phase II). The aqueous phase II 
flow rate was adjusted such that mixed aqueous phase would always have 5% vol. ethanol. 
Aqueous phase II flow rates ranged from 690-460 mL/min. 
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6.2.2.2. Data Acquisition System and Computer Software 
The entire process was controlled by a custom-made program written using National Instruments 
(NI) LabVIEW® software. A data acquisition system (NI PXIe-1078) was combined with 
multiple NI modules to accommodate various input/output signals (e.g. analog and digital 
inputs/outputs, counters, circuit switches, etc.).  The entire system was automated and only 
required the user to define the final lipid concentration and molar ratios of lipid. Process 
variables such as flow rates, pressure, and temperature were monitored and, for some variables, 
automatically adjusted using custom computer algorithms. For example, proportional-integral-
derivative controls were implemented in the computer program to precisely control the flow rates 
of both the ethanol and aqueous phases. 
 
Communication to and from the Malvern Zetasizer was accomplished using the Malvern Link II 
software. Malvern Link II software was setup as an OPC server and NI LabVIEW was setup as 
an OPC client. The z-average particle size and PDI were recorded in the custom computer 
program. The custom computer program was able to send measurement instructions to the 
Malvern Zetasizer. 
 
6.2.2.3. Particle Size Measurements 
All particle size measurements were performed using a Malvern Zetasizer Nano S. Prior to 
measurements, the liposomes were diluted in-line to 5% vol. ethanol and the viscosity and 
refractive index were pre-set in the Malvern Zetasizer software. Particle size measurements 
included the z-average particle size and polydispersity index (PDI). For the off-line 
measurements, disposable plastic cuvettes were used. The samples were equilibrated at 25°C 
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prior to each measurement. Each off-line measurement duration was set for 10 runs at 10 seconds 
each with n=3. 
 
For at-line measurements, a flow cell equilibrated at 25°C was used. The measurement duration 
was set to 1 run for 6 seconds. The Load/Stop Mode, based on loading the flow cell followed by 
stopping the flow prior to the measurement, was used in all cases (see Chapter 5). A 
Micropump® pump was used to control the flow through the flow cell (20-25 mL/min). The 
pump operated at the specified flow rate prior to the particle size measurement. Before any 
measurement took place, the custom computer algorithm stopped the pump to prevent fluid flow 
during the measurement. 
 
6.2.2.4. NIR (Turbidity) Measurements 
An Optek® TF16-N Scattered light dual channel turbidity sensor was used for the 
measurements. This device has two simultaneous channels, the first measures light absorption, 
i.e. this principle is based on detecting the light at 0° from the light source by a single 
hermetically sealed photodiode. This measurement is in concentration units (CU). The second 
measurement principle is based on light scattering and the scattered light is detected at 11° by 
eight hermetically sealed silicon photodiodes. This measurement is reported in parts per million 
(PPM). The measurement wavelengths are a band ranging from 730 nm to 970 nm. The optical 
path length of the sensor is fixed at 40 mm and is in a flow cell configuration, i.e. has an inlet 
and outlet for in-line application. The linearity of the sensor is < ± 1% of the full scale for each 
measurement and has a repeatability of < ± 0.5%. 
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6.2.2.5. Tangential Flow Filtration System 
An EMD Millipore Pellicon Mini Holder with Pellicon 2 Mini Ultrafiltration Biomax-100 
modules was used as the tangential flow filtration (TFF) device. This device was connected to a 
peristaltic pump (Blue-White Industries, LTD) to control the flow rate. A pressure transducer 
and solenoid valve were connected to the output of the TFF device. The pump, pressure 
transducer and the solenoid valve were connected to the custom LabVIEW computer program 
(Fig. 6.1.). 
 
6.2.2.6. Lipid Concentration Analysis via the Stewart Assay 
The Stewart assay is a UV-spectrometric technique that determines the amount of phospholipid 
present. Briefly, ammonium ferrothiocyanate (AF) was prepared by dissolving 13.52 g of ferric 
chloride hexahydrate and 15.2 g of ammonium thiocyanate in 0.5 liters of deionized water. A 
calibration curve was generated by taking 10 – 70 mg of phospholipid stock solution (originally 
dissolved in ethanol) added to approximately 3 mg of chloroform. 2 mL of the AF solution was 
added to this mixture, which was then vortexed for 30 seconds followed by centrifugation at 
1,500 rpm for 2 minutes. The AF was removed and the chloroform containing lipid was analyzed 
using a Cary 50 UV-spectrophotometer at 470 nm. The calibration curve consisted of 9 values 
with a quantitation limit (QL) of 0.023 µg/mL and an R-squared of 0.997. 
 
6.2.2.6. Lipid Concentration Analysis via high pressure liquid chromatograph – Mass 
spectrometry 
The lipid concentration was determined using a high pressure liquid chromatography (HPLC) 
with a mass spectrometer (MS). A Waters Xbridge C8, 3.5 um, 4.6x75 mm column heated at 
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30°C was used for lipid separation. The mobile phase was 2 mM ammonium formate in MS-
grade methanol. The flow rate was set at 0.3 mL/min and 3 µL of sample was injected for each 
measurement. An ESI probe was used and the operating conditions were optimized in the TSQ 
software (table 6.1).  
 
The sample was analyzed for the main phospholipid depending on the lipid formulation, i.e. for 
DPPC. The raw chromatographic data was transformed using a power function value (PFV) and 
the area under the curve was calculated. The tailing factor was less than 1.20 for each peak. The 
calibration curves had a QL of approximately 1.22 ug/mL and the R-squared value was >0.996. 
The PFV used for DPPC was 1.23. 
 
6.2.2.6. Lipid Concentration Prediction Models 
JMP by SAS was used to generate prediction models and equations. Two models (defined as 
Model 1 and Model 2) were generated that had the response as the total lipid concentration 
([Lipid]) in units of mM. The possible factors for the model were the NIR measurements (both 
CU and ppm) the z-average particle size (d.nm) and the polydispersity index (PDI). Model 1 
only included particle size and ppm as factors. Only monodispersed liposome (i.e. having a PDI 
≤ 0.1) were used to generate this model. The experimental design for Model 1 is outlined in Fig 
6.2. Since the ppm signal was highly dependent on the particle size, a typical experimental 
design (e.g. full factorial) was difficult to achieve. In addition, the maximum concentration 
reported for this model was approximately 7 mM total lipid. Higher total lipid concentrations 
would be required to achieve a higher ppm signal for the smaller particle sizes (e.g. 50 nm vs. 
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150 nm). Model 2 is an extension of Model 1 and included particle size, PDI, ppm and CU as 
factors. The experimental design of Model 2 is outlined in Fig. 6.3. 
6.3. Results 
6.3.1. Prediction Models 
The liposomal particle size diameter ranged from 55 nm to 188 nm. For Model 1, the PDI was 
less than 0.10 for all sizes and concentrations tested. The total lipid concentration ranged from 
0.38 mM up to 7.96 mM. The significant terms (P<0.05) were particle size, particle size*ppm 
and ppm (Table 6.2). Both the particle size and particle size*ppm negatively impacted the lipid 
concentration, whereas an increase in ppm related to an increase in lipid concentration. The NIR 
CU measurement did not correlate with the model and was omitted. The R-squared for the actual 
vs. prediction lipid concentration was 0.931, indicating a linear relationship. The model had 15 
observations (with 3 degrees of freedom for the model), a RMSE of 0.587 and an analysis of 
variance <0.001.  
 
The surface profile for Model 1 is demonstrated in Fig. 6.4. The profile is of ppm vs. particle size 
vs. total lipid concentration.  As the particle size increases, the ppm vs. [Lipid] slope increases 
and higher ppm values are reached for lower lipid concentrations. The smaller sized liposomes 
only reached approximately 30 ppm for the same maximum [Lipid], whereas the large liposomes 
reached up to 70 ppm. The empirical prediction equation for the model is in Fig 6.5. This 
equation was implemented into the custom computer program to predict the lipid concentration 
based on both particle size and turbidity measurements. 
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For Model 2, the same particle size diameter range was used as outlined in Model 1 above. The 
total lipid concentration ranged from 0.38 up to 20 mM. Significant terms for Model 2 are listed 
in Table 6.3, with particle size*ppm and ppm as the most significant. Both the CU and PDI also 
had statistical significant terms in the model. The R-squared for the actual vs. prediction lipid 
concentration was 0.987, indicating a linear relationship. The model had 35 observations (with 
11 degrees of freedom for the model), a RMSE of 0.527 and an analysis of variance <0.001. The 
empirical prediction equation for Model 2 is in Fig 6.6. 
 
A validation for both Model 1 and Model 2 was included. The liposomes had a mean particle 
size of 167 ± 4.40 nm and a PDI of 0.05 ± 0.02 (Table 6.4). The total lipid concentration range 
measured was from 1.80 – 7.07 mM. As the PDI was less than 0.1, both models could be used to 
predict the mean particle size, with the mean error less than equal to 7.5%. When comparing the 
percent error of the measured [Lipid] to the predicted [Lipid], a two-tailed, paired t-test resulted 
in a p-value of 0.23, indicating that the differences between the sets of data are insignificant.  
 
6.3.2. Polydispersity on the NIR Signal 
A comparison was made between two sets of data for liposomes of a similar particle size but 
with differences in the PDI. The lower PDI (≤ 0.1) indicates a single population of particles, 
whereas a higher PDI indicates multiple populations of particles present. From Fig. 6.7, it is 
evident that the PDI is a critical factor that must be controlled. The liposomes with a mean 
particle size of 149 nm and a PDI of 0.18 ± 0.02 produced a PPM signal greater than those with a 
mean diameter of 170 nm and a PDI of 0.06 ± 0.02.  
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6.4. Discussion 
6.4.1 Lipid Concentration Model 
The relationship between scattered light and particle size are explained by Mie scattering theory. 
The Mie theory explains light scattering by an induced dipole moment from an incident 
electromagnetic wave. The induced dipole acts as a source of electromagnetic radiation and 
emits or scatters light at the same frequency as the source, i.e. elastic scattering. This theory 
provides an angular dependence of the scattered light based on the incident wavelength and the 
particle size. Relationships between liposomal particle size and light scattering and turbidity 
have been previously analyzed for liposomes.107-109 The theory is based on an approximation of 
the Mie scattering theory, called the Rayleigh-Gans-Debye approximation. From this 
approximation, lipid concentration may be estimated at a fixed incident wavelength if additional 
properties such as the refractive index of the aqueous medium and the refractive index of the 
lipid bilayer are known109. However, this approximation may not be suitable for the current case 
since the incident radiation is a band of wavelengths covering 730-970 nm. In addition, the 
liposomes in this study were both monodispersed and polydispersed, which would further cause 
difficulties in using theoretical approximations to predict the total lipid concentration. For this 
reason, an empirical model was developed to relate liposomal particle size, PDI and the NIR 
signals (ppm and CU) to the total lipid concentration. 
 
As expected, smaller particles scatter less light compared to larger particles. For this reason, the 
ppm/CU increases as the particle size increases. Two predictive models were generated; the first 
for only monodispersed liposomes (i.e. liposomes with a PDI ≤ 0.10) and the second included 
liposomal formulations with a higher PDI (PDI > 0.10). For the monodispersed liposomal model, 
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detection at 0° (measured in CU) did not appear to have any correlation with particle size and 
concentration at the concentrations measured. The CU did increase linearly with an increase in 
lipid concentration, but did not form a correlation when comparing different particle size 
liposomes. In contrast, the scattered light at 11° (i.e. the ppm) demonstrated a correlation with 
both liposomal particle size and total lipid concentration. For this reason, only the scattered light 
was used in the prediction model for monodispersed liposomes. Moreover, since the ppm signal 
is referenced to the medium, the NIR sensor was able to measure low lipid concentrations and 
the detection was not affected by additions to the aqueous phase (e.g. ethanol). 
 
For the second model (Model 2), the CU signal and the particle size PDI were added to Model 1. 
This addition to the model enabled the total lipid concentration to be predicted for both 
monodispersed and polydispersed liposomal formulations. The addition of a polydispersity term 
into the model enhances the overall predictability of the total lipid concentration for both 
monodispersed and polydispersed systems. The validation sample set demonstrated the 
robustness of both models. By comparing the mean error for each model, the error was 
insignificant, indicating that each model could be used for low PDI formulations. However, 
Model 1 could not be used for higher PDI formulations. These results demonstrated that a 
empirical model with only 3 degrees of freedom could predict the particle size of monodispersed 
liposomes; whereas an empirical model with 11 degrees of freedom was required for 
polydispersed samples. Therefore, when liposomes are formed with a low polydispersity, a 
relatively simple and low degree of freedom model may be used to predict the total lipid 
concentration of the liposomes. 
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6.4.2 Polydispersity on NIR Detection 
To emphasize how the polydispersity of the sample negatively impacted the prediction model, 
two data sets were plotted. The result that a high PDI sample increased the scattered light was 
expected as multiple populations of liposomes in the same sample will cause large variations in 
the scattered light. From the Mie theory, large particles will scatter more light in the forward 
direction than smaller particles. In addition, larger diameter particles scatter more light. The 
combination of a change in the angular scattering and scattering intensity prevented this model 
from predicting the lipid concentration. Therefore, a limitation to Model 1 is that it is only 
applicable to monodispersed liposomes. For polydispersed liposomes, Model 2 should be used to 
predict the total lipid concentration. 
6.5. Conclusions 
A tangential flow filtration system was implemented with a continuous liposome formation 
process to continuously concentrate liposomes in-line. Empirical models were developed for 
both monodispersed and polydispersed liposomes that had the total lipid concentration as the 
model response. These models can predict the lipid concentration from 0.38 up to 20 mM total 
lipid for particle size diameters from approximately 50 nm up to 200 nm. One limitation for 
Model 1 is that it is only applicable to monodispersed liposomes. Model 2 has predictive power 
for both monodispersed and polydispersed, but requires a model with 11 degrees of freedom. The 
implementation of the concentrating system and predictive models into a continuous process for 
liposomes enhances process control. Moreover, this system results in effectively controlling an 
important critical quality attribute (i.e. lipid concentration) of liposomal drug products. 
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6.5. Tables 
 
Table 6.1: TSQ HPLC-MS ESI Operating Conditions used in the Analysis of Lipid 
Concentration Quantitation. 
Spray Voltage 4000 
Sheath Gas Pressure 20 
Ion Sweep Gas Pressure 8 
Aux. Gas Pressure 5 
Capillary Temperature 350 
Tube Lense Offset 131 
Skimmer Offset 0 
 
 
Table 6.2: Sorted parameter estimates and model terms for Model 1.  
 
 
 
Table 6.3: Sorted parameter estimates and model terms for Model 2.  
 
 
Term Estimate Std Error t Ratio Prob>|t|
Particle Size (d.nm) -49.1 11.2 -4.4 0.0011*
Particle Size (d.nm)*ppm -46.9 11.9 -3.9 0.0023*
ppm 10.7 6.0 1.8 0.1046
Term Estimate Std Error t Ratio Prob>|t|
Particle Size (d.nm)*ppm -97.0 9.6 -10.2 <.0001*
ppm -66.0 7.9 -8.4 <.0001*
Particle Size (d.nm)*Particle Size (d.nm) 29.9 4.6 6.6 <.0001*
Particle Size (d.nm) -58.7 9.4 -6.3 <.0001*
Particle Size (d.nm)*(PDI-0.102) 86.0 14.6 5.9 <.0001*
CU 53.5 12.0 4.5 0.0002*
PDI 76.0 26.5 2.9 0.0087*
CU*(PDI-0.102)*(PDI-0.102) 1285.5 673.8 1.9 0.069
(PDI-0.102)*(PDI-0.102) 1071.4 608.5 1.8 0.0916
ppm*CU 11.6 9.1 1.3 0.2141
CU*(PDI-0.102) 22.0 29.5 0.8 0.4638
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Table 6.4: Validation data points for both lipid concentration ([Lipid]) models. Model 1 is based 
on particle size and ppm, whereas Model 2 includes particle size, polydispersity index (PDI), 
ppm and CU. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measured 
Value
Total [Lipid] 
mM
ppm CU
Particle Size 
(d.nm)
PDI
Total [Lipid] 
mM
%Error
Total [Lipid] 
mM
%Error
1.80 16.5 0.206 167 0.05 1.81 0.3% 1.78 0.9%
2.62 24.6 0.294 167 0.05 2.77 5.5% 2.56 2.3%
2.78 27.6 0.333 167 0.05 3.12 12.5% 3.00 8.2%
7.07 67.8 0.789 167 0.05 7.89 11.7% 7.88 11.4%
Average 7.5% Average 5.7%
StDEV 5.7% StDEV 4.9%
Model 1 Prediction Model 2 PredictionModel Factors
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6.6. Figures 
 
 
 
Fig 6.1: Schematic of the lipid concentration stage consisting of multiple components such as 
pumps, a tangential flow filtration unit, a flow meter and an NIR turbidity sensor. 
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Fig 6.2: Experimental design of the lipid concentration prediction model based on scattered light 
from an NIR turbidity sensor. 
 
Fig 6.3: Model 2 experimental design for the lipid concentration with factors including particle 
size (d.nm), polydispersity index (PDI), ppm and CU. The PDI was from 0.03 – 0.21, with “low 
PDI” as PDI ≤ 0.1 and “high PDI” as PDI > 0.1. 
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Fig 6.4: Surface Profile plot for the lipid concentration [Lipid] prediction model. The scattered 
light from the NIR turbidity detector was measured in units of ppm.  ppm vs. particle size (d.nm) 
vs. the total lipid concentration (mM) was plotted. 
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Fig 6.5: The Lipid Concentration prediction model equation based on the study outlined in Fig. 
6.2 and Fig. 6.4. 
 
 
 
 
 
 
Fig 6.6: The Lipid Concentration prediction model equation for Model 2 as outlined in Fig 6.3. 
The response for the model is the total lipid concentration denoted as [Lipid] and has four 
factors: particle size (d.nm), polydispersity (PDI), ppm and CU. Both ppm and CU are detected 
by an NIR turbidity meter. 
 
	
	 = −20.1 − 58.7 ∗ 	 − 263238 ! − 66.0 ∗ 
""# − 250
250 ! + 53.5 ∗ 
%& − 2
2 !
+ 76.0 ∗ '( + 29.9 ∗ 		 − 263238 ! ∗ 
	 − 263
238 !
− 97.0 ∗ 		 − 263238 ! ∗ 
""# − 250
250 ! + 11.6 ∗ 
""# − 250
250 !
∗ %& − 22 ! + 86.0 
		 − 263
238 ! ∗ *'( − 0.102+ + 22.0
∗ %& − 22 ! ∗ *'( − 0.102+ + 1290 ∗ 
%& − 2
2 ! ∗ *'( − 0.102+
∗ *'( − 0.102+ + 1070 ∗ *'( − 0.102+ ∗ *'( − 0.102+ 
	
	 = 9.66 − 49.1 ∗ 	 − 263238 ! + 10.7 ∗ 
""# − 250
250 ! 
+*−46.9+ ∗ 		 − 263238 ! ∗ 
""# − 250
250 ! 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
132 
 
 
Fig 6.7: An example of how the NIR signal output in PPM is affected by the polydispersity of a 
liposomal formation. The polydispersity index (PDI) was approximately 0.16 for the high PDI 
sample and was <0.1 for the low PDI sample. In the case of larger liposomes, the NIR scattered 
light signal should be greater. 
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Chapter 7 
 
Freeze-Anneal-Thaw Cycling of Unilamellar Liposomes: Effect on Encapsulation 
Efficiency 
7.1 Abstract  
Freeze-thaw cycling is an important processing step in the preparation of liposomes that leads to 
the encapsulation of drug molecules. There is considerable variability in the number of freeze-
thaw cycles reported in the literature. This work is designed to aid in liposomal formulation 
design by gaining an insight into the drug encapsulation process and an understanding of 
liposome stabilization during various thawing conditions. The effects of different thawing 
temperatures, as well as “annealing” at subzero temperatures on a liposome formulation, are 
reported here. Two freeze-anneal-thaw (FANNT) cycles (freezing to -196°C, annealing at -1.4°C 
for ~30 minutes, thawing at 65°C) resulted in the maximum predicted encapsulation efficiency 
without causing any significant change in particle size or zeta potential.  Annealing at -22°C was 
shown to be destabilizing due to limited hydration of the liposomes in the frozen state. It was 
shown that two important processes are occurring during the FANNT cycling that affect liposome 
encapsulation efficiency. The first is drug diffusion in the frozen state and the second is 
fusion/destabilization of the liposomes. This is the first report on the annealing of liposomes and 
understanding the mechanism of drug encapsulation using the freeze-thaw cycling method. 
 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
134 
 
7.2 Abbreviations 
FT  Freeze-Thaw 
FANNT  Freeze-Anneal-Thaw 
PFE  Pre-formed Empty 
PDI   Polydispersity Index 
EE%  Encapsulation Efficiency Percentage 
DSC  Differential Scanning Calorimetry 
DSPC  1,2-distearoyl-sn-glycero-3-phosphocholine 
DPPC  1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DSPG  1,2-dioctadecanoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
Chol  Cholesterol 
Cryo-SEM  Cryogenic Scanning Electron Microscopy 
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7.3 Introduction 
Freeze-thaw (FT) cycling is a technique often used in the preparation of liposomes to increase 
encapsulation efficiency110-111. A common procedure is freezing the liposomes with liquid 
nitrogen (-196°C) and thawing at a temperature above the phase transition temperature of the 
lipids24-25, 112. In the preparation of liposomes, freeze-thaw cycling is implemented to reduce the 
lamellarity of liposomes20, form a less polydispersed system and/or disrupt the liposomal 
bilayer21 to allow drug molecules to diffuse into the liposome, promoting encapsulation22-24. The 
number of freeze-thaw cycles needed to encapsulate drug molecules varies greatly in the 
literature, with some papers reporting up to 10 cycles113-114. The reason for using multiple freeze-
thaw cycles is to achieve equilibrium drug concentration conditions (i.e. concentration inside the 
liposomes is equal to the concentration outside of the liposomes). Prior to this study, the 
mechanism for drug encapsulation was considered to be due to physical disruption of the lipid-
bilayer as a result of ice crystal formation22. Disruption of the lipid-bilayer typically results in 
vesicle fusion115 and increased polydispersity. In this study a second mechanism for drug 
encapsulation is reported based on cryo-concentration (the phenomenon when water freezes and 
excludes molecules into concentrated zones). Cryo-concentration of the liposome and drug will 
increase drug diffusion into the liposome while the dispersion is in a semi-frozen state. 
Unilamellar, pre-formed empty (PFE) liposomes of a monodispersed population were chosen to 
eliminate any effects related to polydispersity and/or multiple lipid lamellae. The factors that are 
studied include thawing and annealing temperatures as well as annealing duration, where 
annealing refers to holding the samples at constant sub-zero temperatures for a certain duration. 
The freezing procedure was kept constant. 
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To study the effects of drug diffusion in the frozen state, stable DSPC:Chol:DSPG (6:3:1) 
liposomes were prepared and the EE% was calculated. Similar DSPC liposomes have previously 
exhibited minimal particle size changes after freeze-thaw cycling23. This minimal size change 
will allow drug diffusion to be studied while avoiding the effects on EE% from changes in 
particle size/ polydispersity. The EE% for this liposome system was then compared to a 
theoretical maximum EE% based on a mathematical model for the entrapped volume of 
unilamellar liposomes.25 Briefly, this theoretical EE% is based on parameters such as liposome 
size, size distribution, bilayer thickness, average molecular area of a lipid at an interface, and the 
lipid molarity. By supplying these parameters, this mathematical model is able to predict the 
encapsulation efficiency for any unilamellar, monodispersed liposomal system. 
 
As a model drug, Tenofovir was chosen due to its high polarity (LogP= -1.71)116 and low 
membrane permeability. Tenofovir has a pKa of 4.11 ± 0.5 and is negatively charged at the 
studied pH of 7.4. Since the liposomes were also negatively charged, electrostatic interactions 
between the drug and liposome surface were avoided. The significance of this research is that it 
offers physical insight into the behavior of liposomes in the frozen state and provides a method 
to achieve efficient drug encapsulation into unilamellar, PFE liposomes without the need for 
multiple freeze-thaw cycling steps and additional downsizing techniques. 
7.4 Materials and Methods 
7.4.1 Preformed Empty Liposomes Preparation 
1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol and 1,2-dioctadecanoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) were purchased from Avanti Polar Lipids. DSPC:Chol:DSPG (6:3:1 
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molar ratio, 60mM) PFE liposomes were prepared by the film-hydration method. Briefly, lipid 
was mixed with chloroform:methanol (2:1 v/v) and evaporated using a Büchi Rotavapor at an 
elevated temperature (50°C). During evaporation, a low vacuum was applied initially to avoid 
bursting of the lipid solution. Chloroform and methanol were purchased from Fisher Scientific. 
The dried lipid was placed under vacuum overnight to remove residual solvent. The lipid was 
hydrated at 65°C in 10 mM HEPES buffer, pH 7.4 for approximately two hours. The liposomes 
were then sonicated at 80W for 1 minute followed by two freeze-thaw cycles (-196°C for 5 
minutes, 65°C for 10 minutes). The liposomes were then extruded 8x through a single stack of 
one 400 nm and two 200 nm polycarbonate membranes using a LIPEX™ Extruder (Northern 
Lipids Inc.). The extruder was brought to 65°C prior to extrusion. 
 
7.4.2 Drug Encapsulation Process 
Tenofovir (CAS# 147127-20-6) was prepared in 10 mM HEPES buffer, pH 7.4 at approximately 
8.7 mg/ml. This solution was added to the PFE liposomes. The mixture was frozen in liquid 
nitrogen (-196°C) for 3 minutes. The samples were transferred to a temperature controlled water 
bath at various temperatures (Table 7.2). For samples thawed above 0°C, the thawing time was 
determined by measuring the temperature of a duplicate sample until the thaw temperature was 
reached. All samples were placed in a water bath at 65°C prior to extrusion. Extruded samples 
were extruded 6x through a single stack of one 400 nm and two 200 nm polycarbonate 
membranes. Before extrusion, particle size and zeta potential were monitored for most samples. 
After extrusion, particle size, zeta potential and EE% were measured for all samples. 
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7.4.3 Encapsulation Efficiency (EE%) 
Encapsulation efficiency was determined by the following equation: EE% = 1-Cfree/Ctotal, where 
Cfree is the free drug concentration and Ctotal is the total drug concentration. The free drug was 
separated from encapsulated drug by ultra-centrifugation using Amicon 50 kd filters at 4,000 g 
for 12 minutes. Free drug did not interact with the filter membrane and > 99% of the free drug 
passed through the filter. The total drug was determined by lysing the liposomes in a 6% v/v TX-
100 solution. The free drug from the filtrate and total drug was then analyzed using a previously 
developed HPLC analysis117. All measurements were run in triplicate. 
 
7.4.4 Particle Size and Zeta-Potential 
All measurements were performed using a Malvern Zetasizer Nano ZS90. For both particle size 
and zeta-potential, samples were placed in plastic disposable cuvettes and equilibrated at 25°C. 
The viscosity of water was assumed since liposome dispersions were below 0.5 mg/ml. Particle 
size measurements included z-average, PDI, and PDI width. Zeta potential measurements 
included zeta-potential and zeta deviation. All measurements were run in triplicate. 
 
7.4.5 Cryo-SEM Imaging 
In order to determine how annealing can destabilize liposomes in the frozen state, cryo-SEM was 
performed for samples, (1) frozen to -196°C; and (2) frozen to -196°C then annealed at -20°C. 
Both samples were immersed in liquid nitrogen before further processing. The -20°C sample was 
stored in the freezer overnight (~16 hrs).  The samples were then fractured using a Leica EM 
MED020 with an attached cryo-transfer system (Leica EM VCT100). During fracturing, the 
sample was held at -140°C and sputter coated with platinum (5 nm thickness). The sample was 
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then transferred at -140°C under vacuum to the scanning electron microscope (FEI Nova™ 
NanoSEM 450). The accelerating voltage was set to 2.0 kV with a working distance of 5.1 nm 
and viewed at -140°C. 
 
7.4.6 Differential Scanning Calorimetry 
Measurements were carried out using a Q1000 DSC with a Refrigerated Cooling System 90 (TA 
Instruments). Empty liposome samples with Tenofovir (~20 mg total) were pipetted onto an open 
aluminum plate, immersed in liquid nitrogen and then transferred to the DSC holder equilibrated 
at -60°C. The sample was then heated at 50°C/min to either -22°C or -1.4°C. The samples were 
held at this temperature for 10 minutes and subsequently cooled to -60°C at 10°C/min. Only the 
latter thermogram was analyzed. The fast heating rate was used to mimic the thawing conditions 
of the liposome samples used in the EE% tests. 
7.5 Results 
7.5.1 Particle Size 
Particle size analysis was performed to compare the average size and distribution of the particles 
before and after processing. The PFE liposomes that were used in all the following cases had a 
particle size diameter of 166.77± 39.75 nm (PDI = 0.07). As a control, the common procedure of 
freeze-thaw cycling (in this case, freezing at -196°C and thawing at 65°C for up to ten freeze-
thaw cycles) was performed. Since the liposomes were subsequently extruded, the mean particle 
size diameter for all cycles was 153.3± 3.99 nm (PDI = 0.06± 0.02, PDI width = 36.82± 7.47). 
For the test samples, the pre-extrusion particle size and size distribution of FT (thawed at 
temperatures below 65°C) and freeze-anneal-thaw (FANNT) liposomes frozen at -196°C, 
Antonio P. Costa, PhD – University of Connecticut, 2016 
 
140 
 
annealed at -1.4°C for 16 hours and thawed at 65°C [FANNT(-196/-1.416hrs/65)] did not change 
significantly (Fig. 7.1). The PDI did increase slightly for FANNT samples held longer than 90 
minutes, but was still ≤ 0.1 in all cases, which suggests a monodispersed system. The FANNT(-
196/-2216hrs/65) liposomes had a pre-extrusion particle size of 373.20± 263.20 nm and a PDI of 
0.5, which indicates high polydispersity. After extrusion, the particle size was similar to all other 
formulations. 
 
7.5.2 Zeta-Potential 
In addition to particle size measurements, zeta-potential was compared to pre- and post-extrusion 
conditions. Pre-extrusion mean zeta potentials were lower than the post-extrusion mean zeta-
potentials; however, these values were still within the reported zeta-deviation (Fig. 7.2). The 
only sample that did show a major difference in zeta potential was the FANNT(-196/-2216hrs/65) 
liposome sample. This difference is due to the particle size and particle size distribution increase 
noted in Fig. 7.1. In all cases, the zeta-potential did not drop to low levels that would cause 
instability; however, instability may arise from sample polydispersity23 (Fig. 7.2). 
 
7.5.3 Encapsulation Efficiency (Post-Extrusion)  
Fig 7.3 reports on the difference in encapsulation efficiency post-extrusion for all samples. For 
thawing at 65°C, the first freeze-thaw cycle had an EE% of 3.71± 0.23, whereas the EE% was 
7.22± 0.21 after 10 freeze-thaw cycles. Thawing at various temperatures below 65°C followed a 
trend in that lowering the thawing temperature increased the encapsulation efficiency. In all 
cases, annealing increased the EE%. A single FANNT(-196/-1.436min/65) cycle had an 
encapsulation efficiency of 9.83± 0.23%, roughly 2.6 times greater than the FT(-196/65) sample. 
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By increasing the annealing duration, slight increases in EE% were observed but reached a 
plateau around 12%. Lastly, annealing at -22°C increased the EE% into the theoretical maximum 
EE% range. 
 
7.5.4 Two Freeze-Anneal-Thaw Cycles (Pre-Extrusion) 
Another sample was prepared to determine whether the maximum EE% could be reached 
without the need for extrusion while maintaining the particle size characteristics of the extruded 
liposomes. In order to achieve this, two cycles of FANNT(-196/-1.436min/65) were performed 
(Table 7.2). After two cycles, the particle size characteristics were not significantly different than 
the post-extruded samples. The EE% increased to values within the maximum EE% range for 
this formulation. A direct comparison of these results to the EE% results for two freeze-thaw 
cycles (thawed at 65°C without annealing, Fig. 7.3) suggests that sub-zero temperatures near the 
freezing point of the solution allows for increased drug encapsulation. 
 
7.5.5 Cryo-SEM Imaging 
It can be seen from Fig. 7.4 that ice formation (darker, solid regions) causes the liposomes to be 
excluded from regions occupied by ice crystals thus forming concentrated clusters (lighter 
regions). The samples that were only frozen (not annealed) appear to have well-defined 
liposomes with larger clusters of liposomes (Fig. 7.4A, B). For the -20°C annealed sample, the 
liposomes were more difficult to find and either had an overall less-defined/fused structure 
and/or were within narrow bands between the ice-phase (Fig. 7.4C, D).  Moreover, for the -20°C 
annealed samples, there were some locations in the sample that did have clusters of moderately-
defined liposomes. The existence of both clusters of moderately-defined liposomes and large 
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regions of fused liposomes would contribute to the increase in polydispersity as shown in Fig. 
7.1 for the -22°C annealed sample. 
 
7.5.6 Differential Scanning Calorimetry Thermogram 
DSC was performed to determine whether water melted during the annealing process. Heating 
from -196°C to either -1.4°C or -22°C and annealing for 10 minutes before re-cooling to -60°C, a 
peak only appears for the -1.4°C sample (Fig. 7.5). This indicates a portion of the water in the -
1.4°C sample melted and then refroze. HEPES buffer without liposomes was measured as a 
control. The increase in enthalpy for liposomes -1.4°C vs. HEPES -1.4°C suggests additional 
water melted and froze upon re-cooling for the liposome samples. 
7.6 Discussion 
For the liposome formulation investigated here, the theoretical maximum EE% is 16.3±2% 25. 
Accordingly, it would appear that more than half of the predicted drug amount was not 
encapsulated even after 10 freeze-thaw cycles. In order to understand how freeze-thaw cycling 
influenced liposome EE%, all of the liposome samples [except for FANNT(-196/-1.436min/65)] 
underwent a single freeze-thaw cycle. Liposomes were immersed in liquid nitrogen and thawed 
at various temperatures to determine whether the thawing temperature influenced liposome 
physical characteristics. As seen above, thawing at temperatures above 0°C did not significantly 
alter liposome particle size both pre- and post-extrusion (Fig. 7.1), which indicates liposome 
stability. Additionally, the physical characteristics of the samples that underwent FANNT cycles 
did not change significantly except for the FANNT(-196/-2216hrs/65) sample. The reason for the 
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liposome stability at -1.4°C and at temperatures above 0°C may be due to the hydration of the 
liposomes as discussed later.  
 
The EE% was analyzed to determine whether drug molecules entered the liposomes during the 
frozen state. As compared to the control freeze-thaw cycles, adjusting the thawing temperatures 
to less than 65°C showed an increase in EE% as the thawing temperature was lowered. An 
explanation is that at lower temperatures, it takes more time for ice to melt, thus ice growth and 
subsequent cryo-concentration of drug and liposomes increases the amount of drug entrapped 
once the liposomes become rehydrated. Furthermore, complete thawing at 1°C took about 55 
minutes, and the EE% is comparable to annealing at -1.4°C for both 36 and 90 minutes (Fig. 
7.3). As for the annealed samples, increased drug diffusion was evident (EE% > 9% after 1 
cycle). However, the maximum encapsulation (~16.3%) was still not reached, which indicates 
that there was either limited drug diffusion into the liposomes or that only a percentage of the 
liposomes had drug encapsulated. A possible explanation is that under these freezing conditions, 
densely populated liposome phases (Fig. 7.4A, B) are present. These dense phases may inhibit 
the diffusion of the water-soluble drug within the liposome phase. Liposomes located more 
towards the center of this phase and/or liposomes entrapped in the bulk ice would have limited 
contact with the drug. It is suggested that two FANNT cycles are necessary since a second cycle 
redistributes the liposomes, facilitating contact of the drug with all liposomes. After the two 
FANNT cycles, the EE% was similar to the theoretical maximum and the physical characteristics 
did not change. 
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In addition to increased drug diffusion, liposomal disruption/fusion is another mechanism of 
drug encapsulation. This is evident from the FANNT(-196/-2216hrs/65) sample, which had high 
polydispersity pre-extrusion. The post-extrusion polydispersity returned to a monodispersed 
system and the EE% was near the theoretical maximum value. This is due to the complete 
disruption and fusion of the liposomes during the thaw process –after extrusion, the drug is 
equally dispersed between the intraliposomal and extraliposomal space. As suggested by Talsma 
et al. and supported by cryo-SEM imaging (Fig. 7.4C, D), ice crystal growth may be 
destabilizing to the liposomes118 by forcing the vesicles into close contact. At such close 
distances between liposomes, electrostatic repulsive forces and hydration forces95 are no longer 
sufficient to prevent particle fusion. Thus, particle size, size distribution and polydispersity 
increased for the FANNT(-196/-2216hrs/65) samples. For the FANNT(-196/-1.4/65) and FT 
samples, it may be that the high concentrations of drug, liposomes and buffer between the ice-
phase is allowing for intra-liposomal and/or extra-liposomal ice within the vicinity of the 
liposomes to melt, thus keeping the liposomes hydrated and preventing them from fusing. Thus, 
at temperatures close to 0°C, such high concentrations would result in a freezing point 
depression causing the ice to melt. 
 
To further investigate whether ice is melting and possibly hydrating/stabilizing the liposomes at 
subzero temperatures, DSC was used to detect exothermic peaks that indicate water refreezing 
after annealing. Reported DSC measurements for DPPC liposomes demonstrates that heating a 
sample from -50°C to -15°C and re-cooling to -50°C does not show the intra-liposomal water 
freezing peak (at -43°C) in the DSC profile119, thus intra-liposomal and extra-liposomal ice is not 
melting upon heating to moderate temperatures above the intra-liposomal freezing temperature. 
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In the current case, the DSC thermogram from Fig. 7.5 shows that ice melted and refroze for the 
-1.4°C sample. This suggests that melted water is hydrating the liposomes and preventing 
liposome fusion. In the case of the -22°C sample, no exothermic peak was visible, which 
indicated water did not melt during the annealing stage and did not stabilize the liposomes.  
 
Lastly, the results reported here were only for encapsulating a single hydrophilic molecule. As 
previously mentioned, we avoided lipid-drug interactions by choosing a model drug that was 
hydrophilic and exhibited low permeability, and by choosing lipid of the same charge as the 
drug. Therefore, these results can be extended to other small molecules and/or proteins 
(depending on protein stability during freezing/thawing). Moreover, further testing needs to be 
done on lipid composition (e.g. mixing lipids of various hydrocarbon chain lengths, that are 
saturated vs. unsaturated and/or that have different lipid head groups). All of these adjustments in 
the lipid composition may form voids in the lipid bilayer, causing the liposomes to fuse during 
the thawing cycle and resulting in a polydispersed system rather than a monodispersed system 
after freeze-thaw cycling.  
7.7 Conclusion 
The significance of this work is that the results provide further insight into conditions that 
destabilize liposomes and induce fusion (due to dehydration and ice growth). The results also 
suggest a second mechanism for drug encapsulation (i.e., cryo-concentration of drug and 
liposomes in the frozen state) that increases the EE% of the drug. Moreover, for this 
DSPC:Chol:DSPG liposome formulation, it is possible to encapsulate drug into pre-formed 
empty liposomes without the need for extrusion or other downsizing techniques. As for other 
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applications, such as freeze-drying of liposomes, this mechanistic insight provides an 
understanding of why liposomes become destabilized under various different conditions.  
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7.10 Tables 
Table 7.1: Experimental outline for 60 mM DSPC:Chol:DSPG (6:3:1 molar ratio) liposomes.2 
 
 
 
 
 
 
                                                 
2
 A single freeze-thaw cycle was performed in all cases, with differences in the thawing 
temperature. The difference in thawing time was needed to accommodate complete thawing. 
Liposomes were held at 65°C for 10 minutes before extrusion to prevent membrane fouling. 
Sample ID
Annealed 
Temperature 
(°C)
Thaw/annealing 
time (min)
Thawing 
temperature 
(°C)
Time at 65°C 
following thawing 
(min)
FT(65°C) n/a 10 65 --
FT( 1°C) n/a 90 1 10
FT( 4°C) n/a 45 4 10
FT( 23°C) n/a 20 23 10
FANNT(-1.4°C/65°C) -1.4 36, 90, 360 and 960 65 10
FANNT (-22°C/65°C) -22 960 65 10
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Table 7.2. Pre-Extrusion Results for Two FANNT(-196/-1.436min/65) Cycles (n=3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Particle Size ± PDI Width (d. nm) 151.90± 34.97
PDI 0.05
Zeta-Potential± Deviation (mV) -56.77± 10.17
Encapsulation Efficiency 15.42± 0.08%
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7.11 Figures 
 
 
 
Fig. 7.1. Particle size of liposomes under various conditions. Samples either underwent a freeze-
thaw (FT) cycle or a freeze-anneal-thaw (FANNT) cycle. All liposomes were frozen in liquid 
nitrogen (-196°C). All FANNT samples were thawed at 65°C. Both pre-extrusion and post-
extrusion particle size properties are detailed above. The error bar represents the PDI distribution 
width. The inset above each group of data represents the PDI of the samples for pre- and post-
extrusion. 
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Fig. 7.2. Zeta-potential of the liposome formulation. The zeta-potential is provided for both pre- 
and post-extrusion for the samples listed in Fig. 7.1. 
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Fig. 7.3. Encapsulation efficiency for samples thawed under various conditions. All samples 
were frozen in liquid nitrogen at -196°C. The samples thawed directly at 65°C represent normal 
freeze-thaw cycling. All other samples underwent a single freeze-thaw or freeze-anneal-thaw 
cycle. The effects on EE% of thawing at temperatures above 0°C and annealing at subzero 
temperatures is demonstrated (n=3). 
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Fig. 7.4. Cryo-SEM images of PFE-liposomes with tenofovir. In all the images, the 
smooth/darker areas represent the ice phase while the non-smooth/lighter regions are liposomes. 
(A) Sample frozen to -196°C, magnification (mag.) 5,000x. (B) 30,000x mag. of sample from A 
with liposomes clearly visible. (C) Sample frozen to -196°C, annealed at -20°C overnight, and 
then refrozen to -196°C prior to imaging, mag. 5,000x. (D) 30,000x mag. of sample from C. In 
D, the top right hand corner is ice while the rest of the image is of liposomes in an apparent fused 
state. (D Inset) 30,000x mag. of a thin channel of liposomes between the ice-phases.  
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Fig. 7.5. DSC profile of annealed liposomes. Samples were first frozen in liquid nitrogen (-
196°C) and heated to the annealing temperature (-22°C or -1.4°C) and held at that temperature 
for 10 min (not shown). The sample was then re-cooled to -60°C (shown above). HEPES buffer 
without liposomes was shown as a control. All samples were run in triplicate and the average 
standard deviation was <0.4 in all cases. 
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Chapter 8 
 
Conclusions and Suggested Studies 
8.1 Conclusions 
The implementation of the quality by design approach at the onset of this work provided 
valuable insight required for the system design and for an understanding of the liposomal 
formation process. From Chapter 3, risk analyses were performed for various “effects” 
associated with this work, such as “the formation of quality liposomes” and “in-line particle size 
analysis”. From Chapter 4, a turbulent jet mixer was fabricated and investigated in detail. The 
turbulent jet mixer established flow conditions that formed unilamellar, monodispersed 
liposomes. The particle size of these liposomes was controllable from ~25 nm to >465 nm. It was 
determined that the mean particle size of the liposomes had a significant dependence on the 
Reynolds Number of the mixture (i.e. ethanol and aqueous phase) and was independent of flow 
velocity ratios above a flow velocity ratio of approximately 7. The mean particle size and particle 
size distribution of these liposomes was measured using multiple techniques such as dynamic 
light scattering, nanoparticle tracking and two electron microscopy techniques. Each technique 
concluded that the liposomes increased in size with a decrease in Reynolds Number of the 
mixture, and three of these techniques confirmed the monodispersity of these liposomes. In 
addition, a novel model on the liposome formation process was explained. From analyzing 
aqueous phase additives, types of lipid molecules, and lipid concentration on the liposome 
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formation process, it was determined that it is likely that pro-liposomes initially form and grow 
in size depending on process conditions and the lipid formulation. 
 
From chapter 5, an in-line dilution stage was added to the liposome formation process to reduce 
the total amount of ethanol down to 5 % vol. It was determined that the in-line dilution stage 
causes changes to the mean particle size and particle size distribution. This indicates that the 
liposomes may not be fully formed or unstable at the liposome formation site. One major finding 
was that air bubbles caused multiple populations of liposomes to form at the in-line dilution site. 
This phenomenon was thought to occur since lipid molecules would align at the air-water 
interface and then mix back into solution at the in-line dilution stage. When the lipid molecules 
mixed back into the aqueous phase, the liposomes formed at a different Reynolds number and 
possibly temperature, thus forming liposomes of a different size. The combined effects led to 
polydispersity in the system. To prevent liposomal polydispersity, a degassing unit post the 
liposome formation site was implemented. It was determined that low phase transition 
temperature lipids (e.g. DMPC) exhibited a larger polydispersity than higher phase transition 
temperature lipids (e.g. DPPC); however, this polydispersity was reduced for the low phase 
transition temperature lipids when the degassing unit was implemented. 
 
In addition, at-line particle size analysis was implemented into the continuous processing of 
liposomes. Dynamic light scattering was the particle size analysis technique implemented in the 
process. Two modes were investigated to transfer the liposomal dispersion to the instrument for 
analysis. The first was the continuous flow mode and the second was the load/stop mode. The 
load/stop mode provided more consistent results in measuring the particle size of the liposomes 
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For example, this mode exhibited a reduced lag time between process changes and particle size 
measurements and the mean particle size data was similar to off-line particle size measurements. 
Moreover, the amount of NaCl dissolved in the aqueous phase was investigated. It was 
determined that the ionic strength of the aqueous phase significantly impacted the mean particle 
size of the liposomes during the liposomal formation process, i.e. an increase in ionic strength 
formed larger liposomes. 
 
From chapter 6, a tangential flow filtration system was implemented in the continuous 
processing of liposomes. Two empirical models that related factors such as particle size, 
scattered light (ppm) and absorbance (CU) to the total lipid concentration were established. The 
first model (Model I) predicted the lipid concentration from 0.5 to 7 mM total lipid for particle 
size diameters from approximately 50 nm up to 200 nm with an RMSE of 0.587 mM. As 
explained, one of the limitations for this model is that the liposomes must be monodispersed. The 
second model took into account the polydispersity index (PDI) of the liposome formulation. This 
addition allowed for the prediction of both monodispersed and polydispersed liposomal 
formulations, but at a cost of increased model degrees of freedom. 
 
Lastly, from chapter 7, freeze-thaw-anneal cycling on liposomal dispersions was investigated. 
This work provided insight into conditions that destabilized liposomes and induced fusion (i.e. 
due to dehydration and ice growth). In addition, a mechanism to encapsulate drug was suggested 
that was based on the cryo-concentration of the drug and liposomes while in the frozen state. 
This cryo-concentration effect led to an increase in the encapsulation efficiency per freeze-
anneal-thaw cycle. Moreover, the stability of different lipid formulations was assessed. It was 
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determined that high phase transition lipids such as DSPC formed highly stable liposomes that 
were able to withstand freeze-anneal-thaw cycling without change in the physical properties (e.g. 
particle size and size distribution). In this case, drug could be encapsulated during this process 
without the need for extrusion or other downsizing techniques. Lastly, this mechanistic insight 
provides an understanding of liposomal stability during freezing and thawing conditions. 
8.2 Suggested Studies 
8.2.1 Continuous Processing of Liposomes 
From the current work, the liposome formation process was dependent on many factors such as 
temperature, ionic strength, the extent of mixing (predicted by the Reynolds Number), aqueous 
phase additives and the lipid formulation. Additional studies may include investigating different 
types of buffers (e.g. phosphate, hepes or tris buffers), enthalpy of mixing and lipid packing. The 
combination of the previous work with these additional studies may support an empirical model 
to explain and predict the formation of liposomes. This model could then be further investigated 
to establish a theoretical model based on first principles.  
 
In addition, the continuous processing of liposomes has multiple stages and different drugs may 
be intercalated with the lipid bilayer, loaded into the liposomes and/or encapsulated. Additional 
stages could be incorporated into the continuous process to accommodate high 
loading/encapsulation efficiencies of different drugs. Moreover, additional process analytical 
technology (e.g. Raman spectroscopy) could be incorporated into the system to monitor and 
control the drug loading/encapsulation from the beginning of the process to the end. 
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8.2.2 Freeze-Anneal-Thaw Cycling 
This work could be enhanced by developing a method to precisely cryo-concentrate the drug and 
liposomes to achieve high encapsulation efficiency. Future work on developing a freezing 
protocol or an apparatus that forms a highly concentrated liposomal region with drug in the 
frozen state, followed by thawing, may achieve higher encapsulation efficiencies. In addition, 
this technique could be implemented in the continuous processing of liposomes to support the 
encapsulation of compounds that cannot undergo remote loading such as proteins. 
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